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Referee #1 (Remarks to the Author): 
 
Elmentaite et al. here introduce a cell type atlas of the human gut covering different anatomical regions 
across fetal, pediatric, and adult stages. This atlas comprises gut epithelial cells, mesenchymal and 
endothelial cells, secondary lymphoid organ tissue cells, as well as cells of the enteric nervous system. The 
authors first focus on the analysis of the epithelial compartment and describe a BEST4+ CFTR+ enterocyte 
population with a potential role in cystic fibrosis. Based on the analysis of IBD-GWAS genes, they further 
suggest a potential role of PLCG2-dependent inflammatory activation of intestinal tuft cells via FCGR2A 
during IBD progression. They utilize their rich single-cell RNA-seq data for an in-depth characterization of 
differentiation pathways of the enteric nervous system and investigate potential pathways involved in 
Hirschsprung’s disease with impaired differentiation of the immune system. Based on the expression of 
disease-associated ligand and receptors they infer interactions of the neuronal lineage with stromal cells 
such as interstitial Cajal and smooth muscle cells, which could be perturbed in the disease context. 
Finally, they chart cell types driving the establishment of secondary lymphoid organ tissue during 
development, focusing on interactions between lymphoid-tissue-inducer and -organizer cells from the non-
immune compartment. This analysis highlights distinct sub-types of ILC-lineage cells involved in this 
process. Furthermore, with the help of V(D)J sequencing analysis they investigate clonal expansion and 
somatic mutations across different regions of the gut. They utilize their developmental data to infer SLO 
developmental pathways that are potentially reactivated for aberrant lymphoid aggregate formation in the 
context of Crohn’s disease. 
 
The atlas introduced in this study represents an incredibly rich resource for investigating the dynamic cell 
type composition of the human gut during fetal, pediatric, and adult periods of life. The authors 
demonstrate with a number of examples that the atlas can be integrated with prior knowledge on disease-
causing mutations and/or candidate disease-driver genes, to infer novel hypotheses on aberrant pathways 
and intercellular interactions involved in disease progression. This underscores the critical relevance of this 
resource as a basis for identifying novel therapeutic approaches to treat common intestinal malignancies 
such as IBD and Crohn’s disease. 
The quality of the data and the analysis is very high and the manuscript is well-structured and concisely 
written. The figures focus on the relevant information and present data in a clear and intuitive way. 
Crucially, the authors provide a rich web interface, which makes the data easily accessible also to non-
experts and permits overlaying multiple layers of information in UMAPs such as gene expression, 
developmental stage, organ of origin, donor ID etc. 
 
This resource represents a significance advance for the research and medical community. Nonetheless, I 
do have a number of concerns that need to be addressed by the authors: 
 
 
1. Among the annotated epithelial clusters I did not see sub-clusters of SST and SCT expressing 
enteroendocrine cells. I would expect to observe these cells at least in the adult samples (not sure about 
the presence of these cells in fetal gut). In general, it would be good to annotate for which stages and 
which anatomical regions a given cell type can be observed. The authors should also explain in more detail 
how they arrived at the 103 cell types obtained by clustering. How did they determine which parameters 
to use for clustering (in particular, how were the resolution parameter and number of principal 
components selected)? Is the list of 103 cell types likely to be complete or do the authors anticipate that 
further resolution-increase is likely to reveal additional distinct sub-types? 
 
2. The data shown in Figure 1F actually indicate expression of SCT in fetal enterocytes. I would expect to 
find expression of secretin only in hormone producing secretory cells. It is also not clear to me from the 
legend, if the dot plot highlights expression only for enterocytes or for all cells at the respective stage and 
region. 
 
3. When the authors describe their finding of BEST4+ enterocytes across human small and large intestine 
(line 133), they should also mention that these cells have been described across these regions before and 
cite the corresponding paper (Ito et al., ref. 54), which they mention in the discussion. 
 
4. In the discussion, the authors mention that BEST4+ enterocytes have only been described for the colon 
(line 554), and they cite ref. 54 (Ito et al.). However, the study clearly describes the presence of BEST4+ 
absorptive enterocytes in the small intestine and colon as well, in contrast to BEST2+ goblet cells, which 
were only found in the colon. Did the authors also look for differential presence of these BEST2+ goblet 
cells across life stages and tissues? 
 
5. It would be helpful to include a pathways enrichment or GSEA analysis in BEST4+ versus BEST4- 
enterocytes, and between BEST4+ cells found in small intestine versus colon. What is the function of these 
cells during homeostasis? 
 
6. CFTR expression in epithelial cells could be relevant for mucus production by nearby goblet cells, for 
instance, by hydrating the mucus layer, and avoiding organ obstruction by a thick mucus layer, which 
could represent a first step of inflammatory disease. It would be interesting to investigate co-localization 
of BEST4+ cells with goblet cells. Could these cells have a specific role in aiding mucus production by 
goblet cells? 
 
7. Is it possible to derive EEC differentiation trajectories from NEUROG3+ enriched in samples of the first 
trimester towards the different mature sub-types observed starting from the second trimester? Could the 
authors predict which pathways trigger maturation of this lineage between the two developmental stages? 
 
8. The authors hypothesize that IgG sensing of tuft cells via FCGR2A activates PLCG2 and may affect the 
inflammatory response of the gut. Is there any evidence for a physiological role of PLCG2 in the context of 
inflammation. To complement the organoid experiment it would be informative to test whether this gene 
(and also Fcgr3) is up-regulated upon treatment of mice with inflammatory cytokines or in IBD mouse 
models (using data from published studies). With regard to the organoid experiments the authors should 
address whether up-regulation of PLCG2 is due to increased expression in tuft cells or other cell types, and 
whether FCGR2A also increases in expression upon treatment with inflammatory cytokines in tuft cells 
specifically. 
 
9. Regarding the characterization of gut ILCs, I’m not convinced about the classification into ILC3s and 
ILCPs. I would expect up-regulation of KIT and ITGB7 in ILCPs versus mature ILC3s. I would also expect 
reduced levels of RORC in ILCPs versus mature ILC3s. The cells classified as ILC3s also have increased 
levels of ID2 compared to ILCPs and do not express IL17A which argues against their classification as 
mature cells. Since the cells classified as ILCPs up-regulate ZBTB16 and TCF7 I do believe that they could 
correspond to progenitors, however, I doubt the classification as mature ILC3s is correct for the respective 
cluster. Please also show additional progenitor markers from Lim et al. (2017) Cell, such as Cd7 and Il1r1. 
Do the ILCPs also express markers of ILC1s and ILC2, i.e., T-BET, CRTh2, and GATA3, at low levels? 
 
10. What is the meaning of the arrows in the UMAP of Figure 2? I could not find a description in the 
legend. 
 
11. The description of the Milo method is too superficial. It is unclear to me how the authors control for 
overall differences in numbers and relative abundances (which might be of technical nature) between 




Referee #2 (Remarks to the Author): 
 
Elmentaite and colleagues report here a vastly comprehensive catalogue of cells and single cell gene 
expression patterns, throughout different intestinal tissues and human age. This is an impressive 
catalogue (a word used by the authors), which the authors use to map cells involved in pathologies, such 
as IBD and Hirschsprung’s disease. They also use this database to identify pathways that regulate Tuft 
cells and type 2 immunity, and the LTi-LTo crosstalk required for the development of lymphoid tissues 
during ontogeny and chronic inflammatory pathology. 
 
In my particular field of expertise, immunology and the development of lymphoid tissues, the biology 
developed in the manuscript is precise and correct, and the interpretation of the data largely confirms 
previous knowledge. I have to confess that it is however extremely difficult, for me, to have a critical 
appreciation of the data, which is consists mainly of scRNAseq data treatment. Therefore, given the 
correctness of the interpretation, and my inability to judge the quality of the data, I cannot manage to 
propose sensible revisions. 
 
In sum, this manuscript is impressive in its scope and quantity of data, interpretation pertaining to my 
area of expertise is correct, but net advancement in knowledge is limited. This study will nevertheless 
provide the field with an invaluable resource. 
 
 
Referee #3 (Remarks to the Author): 
 
The manuscript by Elmentaite et al provides a new human gut cell atlas encompassing single cell RNA-
sequencing analysis of fetal, pediatric and adult cell populations. 350 000 high-quality intestinal cells are 
included representing various gut cell types at distinct anatomical positions. The presentation focuses on 
1) the epithelial compartment, highlighting distinct BEST4+ in small intestine versus colon and proposing 
tuft cells in the pathogenesis of IBD by IgG sensing 2) the gradual differentiation of ENS from ENCCs, 
highlighting presence of many glial populations and interactions with claimed relevance for Hirschsprung’s 
disease 3) genetic programs controlling lymphoid structure formation, highlighting its reactivation during 
pediatric Crohn’s disease. 
 
The study forms a valuable resource for a vast range of intestinal research and gives an impressive 
description of the gradual development and maturation of the human intestine including associated 
mesenteric lymph nodes. However, as a whole, the manuscript represents a patchwork of topics, each 
alone with limited depth sometimes suffering from far-fetched conclusions. The manuscript would be much 
improved if the data-sets would be presented as a resource and speculative aspects moved to the 
discussion. It will important to justify how your atlas stands out and compares to the many recent 
publications describing the developing and adult gut by RNA-seq (see also major issue 4; e.g. Fawkner-
Corbett et al., Cell 2021; Han et al., Nature 2020; Holloway et al., Cell Stem Cells, 2020; Cao et al. 
Science 2020). Alternatively the manuscript could be split - several impactful studies (up to 3) could 




1) Presence of small intestine BEST4+ cells is claimed as a novel finding in the abstract and introduction, 
although BEST4+ cells have previously been reported across the human intestine including both small 
intestine and colon with regular immunohistochemistry (Ito et al., 2013 PLoS One). The present 
manuscript describes however a very interesting regional difference between the BEST4+ cells that are 
appropriate to high-light. Please rephrase the major finding in the abstract and introduction (perhaps 
focusing instead of the transcriptional difference between BEST4+ cells in colon and small intestine?). 
 
2) PLCG2 expressing Tuft-cells: 
a) The presumed link between IgG sensing Tuft cells and IBD are built on several assumptions forming 
circumstantial reasoning. For many IBD risk genes, the cells in which the gene acts has not been 
established. In the case of Plcg2, an obvious role within the immune system is shown. It is possible that 
the small proportion of Tuft cells are IgG sensing via Plcg2 and could contribute to disease, but convincing 
evidence are lacking herein. What is the evidence for that Fcgr2a can upregulate Plcg2? Is Fcgr2a 
expression increased in CD patients material? The suggested link is to this reviewer too weak to be high-
lighted in the results section. It would be more appropriate to more generally suggest signaling pathways 
involved in the immunological responses of Tuft cells, where Plcg2 could be one plausible gene. The 
possible role in IBD belongs to the discussion. 
b) The presumed receptor activating Plcg2 is expressed in a very small proportion of Tuft cells (2,5%). 
Despite this, organoid cells upregulate PLCG2 upon TFNFa or IFNg treatment. Do you also observe an 
upregulation of Fcgr3 (or other ITAM receptor) following the treatment that could help boost the presumed 
signaling pathway? Similarily, is the receptor increased in CD patients? 
 
The lead is interesting, consider to continue this project to substantialize the findings and separate this 
part into an own manuscript. 
 
3) Analysis of the developing ENS has several issues that need to be addressed. 
a) Overall Analysis: The ENS develops through a protracted time period and neuron subtype specification 
appears to depend on time of birth (Pham et al J, Comp Neurol. 1991, Bergner et al. J Comp Neurol 2014) 
as well as post-mitotic neuronal conversions in mouse (Morarach et al, 2021 Nat.Neuroscience). 
Additionally, it is likely that the enteric progenitor population develops with time in analogy to the gradual 
differentiation of neural tube progenitors to “radial glia” phenotype in the CNS, upon which Blbp amongst 
others markers are increase in expression. Moreover, submucosal plexus only starts to be generated by 
W12-14 and colonic ENS will partly consist of sacral neural crest, likely having a different expression 
profile compared to the vagal neural crest progenitors. Thus, to be able to investigate discrete 
differentiation processes, regional and temporally different data-sets will need to be analysed in separation 
from one another. It appears as if the vast majority of the analysis is performed with cells merged from 
the whole neurogenic period at all regions (thus a span of 77 days!). While an overall view with all stages 
should be shown and is informative, a detailed analysis of gliogenesis, neurogenesis and neuronal 
specification is likely hampered by inclusion of all stages/regions. A separation of for instance W6-10; 
W10-14 and W14-17 by the region would likely give better basis to clearly follow differentiation and 
branching events. This suggestion might resolve some of the specific issues identified below: 
 
b) Committed glial precursors: It is not trivial to discern glial committed precursors from ENCCs or 
differentiated enteric glia. Higher levels of markers associated with adult glia would not necessary indicate 
glial-committed precursors (could also indicate a more mature progenitor population that is still bi-potent). 
It is not clear which genes are used to define committed enteric glia. If it is those specified in methods 
part (Sox10, Mpz, S100b, Erbb3, Plp1, Gas7, Col18a1), please refer to appropriate confirming paper or 
propose a reasoning to picking these genes. The mentioned markers for this population (AGRM and SGO2) 
are also un-suggestive to mark glial committed precursors. AGRM is a known marker of radial glia that are 
multipotent (Marinaro et al., 2011 PLos One) and SGO2 has been shown to regulate mitosis (Gomez et al., 
EMBO Rep 2007). The expression of CCNA2 and CCNB1 also points to that this population corresponds to a 
specific stage during the cell cycle. A committed glial precursor population would show all phases of the 
cell cycle – is that the case? Moreover, your data indicate a higher proportion of committed glia precursors 
at early stages (Figure 4B), while it is known that neuron differentiation proceeds glial differentiation in 
the developing ENS (although it is much more simultaneous than in the developing CNS). As suggested 
above, separation of data by stage (and perhaps region) would make the interpretation easier. 
 
c) Committed neuronal precursor: From the Velocity analysis these cells are probably committed to 
becoming neurons, going through their last cell-cycle, ie neurogenic. Would it be better to call them 
neuroblasts or neurogenic cells? These cells are expected to transiently express proneural genes such as 
higher ASCL1 while downregulating progenitor genes (Sox10, Sox2) and upregulating early neuronal 
genes (Tubb2, Pgp9.5, Elavl4). The neurogenic population has been defined in murine ENS (Morarach et 
al., Nat. Neurosci 2021) and it could be useful to utilize this information to annotate the human neurogenic 
phase (although of course some gene are likely to differ, the majority of genes are probably conserved). 
For instance, Mfng, Dll1, Dll3 are also markers of murine neuroblasts. 
 
d) Annotation of Enteric Neuron Subtypes: The branches and logic of enteric neuron diversification in the 
mouse have recently been defined (Morarach et al Nat. Neurosci 2021). At neurogenesis, a binary event 
separates Etv1+ precursors (Branch A) from Bnc2+ precursors (Branch B), thus the same transcription 
factors observed in your human dataset. Branch A differentiate into Enteric Neuron Classes (ENC) 8-12 – 
corresponding to inhibitory motorneurons (Nos1/Gal/Vip), Neurod6+ putative interneurons as well as 
Ntng1/Nxph2 neurons that possibly could be a mix between atypical IPANs and interneurons. Branch B 
differentiate into excitatory motorneurons (Penk+/Tac1+), IPANs (Nmu+, Dlx3+, Ano2+, Nog+, 
NTrk3+…), Interneuron/Intestinofugal Unc3/Cck cells and Sst+ putative interneurons. UMAP structure and 
Velocity analysis suggested that most neuron classes diverge at postmitotic stages by gradual conversions 
within the branches. Basic developmental processes are often conserved between species and authors 
could be helped to analyse their branching events and neuron types by consulting this framework in 
mouse. 
 
The current attempts to annotate neuronal subtype is partly questionable, relying solely on the recent un-
validated annotation of enteric snRNA-seq clusters (Drokhlyansky, Cell 2020) ignoring a large body of 
literature already present used to identify enteric neuron subtypes. The Drokhlyansky atlas refer to all 
CGRP+ cells as sensory, although several other neuron populations express this marker, including the 
cholinergic secreto/vasodilatory neurons that were expected within that atlas but not annotated. The 
Drokhlyansky PSN1 is likely corresponding to IPANs, while PSN2-4 would need to be confirmed (these 
correspond to the murine ENC7, parts of ENC12 and likely cholinergic secretomotor/vasodilatory neurons). 
Consider to also consult May-Zhang et al., Gastroenterology for human IPAN characterization (both with 
RNA-seq and tissue staining). Please note that CGRP appears mainly transcribed from CALCB rather than 
CALCA in the ENS. 
 
For you annotation of possible enteric submucosal neurons, please note that this layer start to arise at 
around W12-14 (Fu et al., 2004. Anat. Embryol 208:33-41.) -thus your stages W14-W17 should primarily 
be used to annotate these neuron types. The number of neurons at these older stages appear however 
limited, which might make such identification difficult. The markers you indicate (Vip, Etv1, Scgn and 
Unc5b) are also expressed in myenteric subpopulations, why caution should be taken to annotating 
submucosa based on these genes. Note that murine IPANs (ENC6) express Unc5b, while Scgn is expressed 
in murine ENC7 (mature markers CCK/Ucn3) and ENC10 (Neurod6+). Thus, with further investigation of 
murine datasets you may be able to link Branch 1 to ENC6/7 and Branch 2b to ENC10. An alternative to 
annotate cells by function is to refer to the Class number (Enteric Neuron Classes 1-12 in the mouse 
myenteric plexus). Future functional experiments will be needed to faithfully annotate the neuron clusters 
into functional classes. If you find enough similarity between murine and human neuronal differentiation 
consider to use the same terminology as used in Morarach et al (Branch A, B; myenteric ENC1-12) for 
future clarity in the field. 
 
e) Annotation of Glial classes: It is a hard to follow the annotation and reasoning for enteric glia and 
schwann cell-like clusters. All three schwann-cell like types are first defined as Schwann Cell Precursors 
(Row 268), while this term later in the text only denotes a subtype. It is also unclear why the markers 
PLP1, PMP22, CDH19 and ITGA4, CDH2 are used to define SCPs. No reference markers for human 
schwann cell precursors/cells that distinguish these from developing enteric glia has been published (if 
there is, please cite). All these markers are however robustly expressed within murine enteric glia (see: 
mousebrain.org – enteric glia, Zeisel et al., Cell 2018). Dhh is the only marker known to this reviewer that 
would faithfully distinguish schwann cell precursors from ENCCs (again this is from mouse studies 
including Uesaka et al., 2015). 
 
It would be advisable to re-think the nomenclature for the glial subtypes considering the following: 
Myelin SCP: Are you sure that myelinating Schwann cells are present in the mesentery and/or gut wall? 
Expression of Mpz is not a valid reason to call this a myelinating type as this is an early marker of schwann 
cells in general (Jessen and Mirsky, 2019, Frontiers in Mol Neuroscience). This glial type could correspond 
to the (unvalidated) putative SCP found in mouse ENS (enriched Mpz, Mal, Wnt6, Gfra3 and Dhh; 
Morarach et al, 2021). Your validation of Dhh+ cells in mesentery (fig 3) does not rule out the presence of 
these cells within the gut wall, please re-analyse this possibility (given that Dhh+ cell in mouse infiltrate 
the gut wall and give rise to neurons at postnatal stages, Uesaka et al, 2015) 
Non-myelinating Schwann-like: What is the reasoning to denote this type schwann-like? The murine 
enteric glia consist of many subclasses (see Zeisel et al., 2018; mousebrain.org – enteric glia). These 
express variable levels of Eln, Sox8, Apoe, Bcan. Consider if your “non-myelin schwann-like cell” instead 
could correspond to a subdivision within the enteric glia 
SCP: Please validate the presence of this cell type in tissue (as was performed with non-myelin Schwann 
cells with BMP8B). It is misleading to state enrichment in first trimester. These cells peak at W10 and are 
present with similar proportions at W9 as w17. Stating the age of first detection would be more 
informative. 
In conclusion, considering no validation and functional analysis of glial populations, could they be 
annotated as enteric glia 1-4 in this atlas? 
Does the velocity and UMAP look more crisp if only relevant stages (W9-17) are included in the analysis of 
glial clusters and differentiation? Are the different glial populations regionally distributed (colon versus 
small intestine)? 
 
f) Acknowledgement of present literature of the developing human ENS: Several of the identified signaling 
molecules have previously been investigated in the developing human ENS in an immunohistochemical 
atlas comparing murine and human ENS transcriptional and signaling regulators (Memic et al., 
Gastroenterology 2018). It would be appropriate to use this resource as validation for expression scRNA-
seq. For instance, the mentioned GDF10 as well as other TGFB-receptors Tgfbr1, Tgfbr2 and Tgfb2 protein 
expression have been detected at W6-10. The Branch 1 specific transcription factor Etv1 is also validated 
in human ENS within the same atlas. 
A very recent paper (Fawkner-Corbett et al., Cell 2021) also characterizes the developing human ENS 
(week 12-19), please refer to this paper and compare with your own analysis. 
 
g) Hirschsprung disease risk genes in dataset: Risk genes for HSCR are extensively investigated and have 
resulted in the identification of many genes that can explain the aganglionic phenotype (replicated in 
murine models). RET, GDNF, NRTN, SOX10, EDNRB, EDN3, ECE1, ZFHX1B, PHOX2B, KIAA1279, TCF4 are 
major HSCR risk genes. Studies have also linked SEMA3A, MAPK10, NRG1, SOX2, BACE2 and GFRA1 
(Tang et al., Gastroenterology 2018). Note that genes involved in ENS development have been 
investigated as candidates in many studies, where some have been linked (HOXB5) - while others have 
been disproven to contribute to HSCR, including ASCL1 (Carter et al., 2012 J Hum Genet.) Please limit 
your annotation to confirmed HSCR-disease linked genes and do not include own candidate genes (remove 
ASCL1, TLX2 and possibly others). Carefully review your HSCR risk genes. The illustration in major Figure 
4G is questionable as it fails to illustrate the fine validation provided by this paper of already suspected 
transcription factors, cell-interactions and receptor/ligand interactions and instead high-lights new 
interactions that are not substantialized by experiments nor warranted from unexplained phenotypes in 
HSCR. Instead, for the HSCR field to gain the most from your resource , please make a Table similar to Fig 
4f or Sup 4l with all significant HSCR risk genes. This could identify new leads to be followed up by 
experiments. It is for example very interesting that Ret is higher expressed in the colon than in the small 
intestine. Note that ERBB2 and NRG1 variants are only found in very few HSCR patients and that there are 
other sources of NRG1, including sub-epithelial mesenchyme (Holloway et al., Cell Stem Cell In Press) and 
smooth muscle cells and fibroblasts (Elmentaite et al., Developmental Cell 2020). It is also fine to include 
genes previously implicated in ENS development either in the same or separate table, but they could be 
denoted “critical for ENS development” or something similar. 
 
It is however true that patients do experience life-long complications including enterocolitis (Gosain et al 
2016 Pedatr Surg Int) and an increased risk to develop Crohn’s disease (Granström et al., 2017 JPGN). 
Hence, there are aspects about HSCR that we still do not understand that possibly extends beyond ENS 
differentiation and colonization. However, the “new” cell-cell interactions indicated by receptor-ligand 
matching do not seem to reach these gaps in knowledge, are highly speculative, not backed up with 
functional evidence or HSCR tissue stainings. Your conclusions that the analysis implicate fetal branch 2b 
and ICC/SCM interactions in pathogenesis of Hirschsprung disease (results) and that your high resolution 
genomic definition uncovers new insights into both rare and common diseases (in the introduction), 
represents two statements that are exaggerated. Please refrain from too much speculation. It is enough to 
show the gene expression of HSCR genes in your different cell populations and conclude that they are 
expressed more wide-spread than previously appreciated (or in novel cell populations). Please amend 
figures, introduction and results accordingly. 
 
h) Unnecessary speculation: Page 7 row 326: Authors identify NTrk3 expression in an glial population 
(denoted pro-myelinating schwann cells) and try to link this expression to the previous observation of 
reduced IPANs in NTrk3 or Nt3 mutant mice. However, Ntrk3 is expressed in IPANs (Morarch et al., 2021), 
so a much more straight-forward explanation would be the intrinsic expression of this receptor. Please 
remove this speculation. 
 
4) The authors admit that extensive single cell sequencing of human gut tissue at different stages has 
collectively been carried out in recent time and indicate that they intend to provide a holistic analysis. As 
such it would be very helpful for the field if the authors could put their new atlas into perspective of 
recently published studies. For instance, how does the human gut RNA-seq dataset and analysis of Han et 
al., 2020 Nature; May-Zhang et al., Gastroenterology 2020; Drokhlyansky et al., 2020; Holloway et al., 





1) At many location, you refer to the ENS as “Neuronal” (Figure 1, Supplementary Figure 2, Results, 
Introduction). It is more appropriate to use the term “Neural” as this encompasses both neuronal and glial 
types/fates. Please change Neuronal to Neural when you refer to the whole ENS. 
 
2) Figure 1A. Labelling of sampled areas on fetal tissue only states ileum. The proximal and mid ileum 
appears to be placed in the fetal duodenum and jejunum. Please correct sampling area or labelling of area. 
 
3) P52; row 168. 3 is missing in NEUROG+ 
 
4) Supplementary Figure 1b. The label indicates presence of Glia in red, however no such cells are 
discernable in the figure 
 
5) Page 6; Row 265: It is questionable to refer to terminal glia markers Plp1, Sox10, S100b and so as 
“neural crest precursor genes”. Perhaps it is enough to define these markers as terminal glial markers 
without referring to neural crest. 
 
6) Page 6 Row 242: What do you mean by “a shift” in ENS development? Why did such shift enable ENCC 
investigation? 
 
7) Bnc2 is misspelled in results and figure legend 4. 
 
8) Abstract: It is enough to say that you define glial and neuronal cell populations in the developing 
enteric nervous system (no need to say novel – most are already defined in the mouse). If you want to 
use novel, only the glial subsets appear truly novel and previously not described. 
 
9) Page 3; Row135: Reference should be Figure 1E,F. 
 
10) Page 5; Row 190: Rephrase “IBD pathogenesis is due to”, you probably mean “IBD pathology is due 
to”, or “IBD pathogenesis involves impaired intestinal….” 
 
11) There are duplicated papers in the reference list (for instance Drokhlyansky) 
 
12) It would be helpful with a table indicating the number of cells in each sample type and the 103 cell 





Referee #4 (Remarks to the Author): 
 
This very broad-ranging, highly ambitious study examines fetal, pediatric and adult gut and lymph node 
tissues at single cell resolution, including 11 distinct intestinal/secondary lymph node locations. Strengths 
of the study include its "time and space" analyses, providing invaluable single cell insight into gut 
development. The sharing of data and code through the Human Cell Atlas and will provide an enormously 
useful resource for the community. The time-series analyses provide an important re-definition of gut 
development at the single cell level. This is effectively leveraged for advancing Hirschsprung's disease 
(aganglionic megacolon) pathogenesis, a developmental disorder, but somewhat less so for inflammatory 
bowel disease (IBD). 
 
Major 
1. Consistency and developmental differences in sampling capture. Supplementary Table 1 should include 
cellular yields for each of the samples (EPCAM+/CD45-, CD45+EPCAM-) to provide insight into the 
consistency, replicability and robustness of findings. This is particularly important as many of their figures 
with respect to time-series changes may reflect only one sample (would be important to clarify). The 
description of the pediatric ileal tissues is not described beyond enteroid recovery; however, additional 
pediatric tissue results are reported beyond epithelial cells. The description of the fetal and adult tissue cell 
isolations implies that full-thickness digestion was performed; given their sorting strategy, how do the 
authors interpret the marked relative mesenchymal enrichment observed in fetal tissues, relative to post-
natal tissues (Figure 1C)? Full-thickness digestion and differences between fetal and post-natal processing 
and cell capture efficiencies will have marked differences in the interpretation of many items in Figure 1. 
 
2. Figure 2A-B is a highly interesting time-series analyses of relative cell fractions, which effectively 
leverages the strength of this study, namely the time-series fetal datasets. As classified presently, there 
are marked small vs. large intestinal differences prior to the "developmental shift" defined in Fig 2B as 
between 10-12 weeks. For example, for the large intestine, the "crypt" clusters" arise quite abruptly after 
the "shift" which doesn't necessarily make sense, as large intestinal crypts include both enterocytes and 
goblet cells. Also, LGR5 and other stem cell markers, should anchor the crypt development descriptions. 
Ideally, the empiric serial fetal fractions (Fig 2B) could empirically justify the time-series predictions more 
explicitly (Fig 2A), especially with respect to the secretory vs. transit-amplifying/enterocyte dichotomy. 
Missing in the large intestinal analysis is a description of the Paneth cell equivalents, described by some 
groups as REG4+ cells. Finally it is well known that even within small or large intestine, marked cellular 
composition differences exist between regions (proximal to distal), so in text and/or more concise 
summaries in supplementary materials (e.g. UMAPs by regions with small or large intestine) should be 
provided. 
 
3. Figure 2E-G: The findings of immune receptors, especially for IgG on Tuft cells is potentially quite 
important, but with the present datasets, the IBD connection is quite speculative; lines 190-198 and 226-
239 are not particularly informative. Rather, I interpreted pre-natal presence in the context that IgG 
uniquely can traverse the placenta, thereby providing passive immunization generally and potential to 
activate Tuft cells. Post-natally, tuft cells mediate type 2 immunity, and Crohn's disease is clearly a type 1 
response; the modest increase in PLCG2 (Supp Fig 3E) is not a particularly compelling/strong tie-in to IBD 
pathogenesis. I could not understand what points were trying to being made in Fig 2D with the Crohn's 
disease vs. ulcerative colitis comparison, and deleting these sections should be strongly considered, 
especially as this general tie-in is alluded to in their Developmental Cell 2020 manuscript. 
 
4. The application of their datasets to Hirschrung's disease genes (e.g. Ret, EDNRB) provides a fascinating 
glimpse into disease pathophysiology with interesting validation by RNAscope (Fig 3D) at 15 PCW (the 
failure of ganglion cell migration is believed to be prior to this timepoint). However missing in Figure 3 is a 
time and space summary of this migration defect (proximal to distal). At the earlier fetal timepoints, can 
RNAscope be applied to track proximal-to-distal migration of ganglion cells? From a translational 
perspective, short segment (vs. extensive) Hirschsprung's only affects the distal rectum, so it would be 
interesting to track a bit more precisely the timing of colonic innervation. 
 
5. Figure 4. The focus on ILC populations is merited, especially given the connection to IBD GWAS genes 
in Figure 5G. However, no mention is made of ILC2 or ILC1 cells (Yudanin Immunity 2019). Were they not 
observed? There is a literature that ILC1 cells can derive from ILC3 cells over time, and certainly in IBD. 
Figure 4E is a lovely juxtaposition of CXCL13 (from follicular dendritic cells?), CXCR5 and RORC (LTi-like 
ILC3). Would be highly informative to provide a corresponding RNAScope co-segregation analysis for the 
LTi-like NK/T cells, especially given the anti-inflammatory nature of IL17A in Crohn's disease. Along these 
lines, it would be illuminating to also provide gene expression values for IL22 (epithelial protective) and 
IFNG (multiple cellular sources). 
 
6. Fig 5. While it is logical to conclude the mansucript with gut to MLN connections, as presently 
formulated, compelling, novel and crisp conclusions are not provided. Regarding Fig 5G, not sure why they 
chose to test cellular enrichment for Crohn's disease as opposed to ulcerative colitis, where the 
roles/impact for leukocyte trafficking is stronger for the latter. While Figure 5G clearly shows substantial 
overlap in effects between different cell types (likely all cells contribute to some extent) the text concludes 
by emphasizing ILC3 cells (again logical), at the expense of Treg cells, with the latter having the highest 
enrichment. The role for differential expression in single cell datasets as a means of implicating cell 
subsets is logical, but added rigor would be attained by applying a complementary datasets (Encode, 
transcriptionally active regions, e.g Farh et al., Nature 2015). The Farh et al., manuscript implicates Th17 
cells and not B/plasma cells particularly. Given the sparse transcriptome, it is quite possible that single cell 
approaches lack the sensitivity to identify key disease causing genetic variation. 
 
7. More generally, the discussion should include caveats about the lack of sensitivity of the scRNASeq 
approaches. Even if scRNASeq co-localizes Best4 and CFTR, validation of an exclusive co-localization by 
protein staining (Supp Fig 2F only shows CFTR) is not provided. 
 
MInor: 
1. Figure 2A: did the authors mean to label the upper left-hand cluster "EEC" as opposed to "ECC"? 
2. 4 pediatric samples listed in Figure 1A, yet multiple subsequent figures allude to 5 pediatric samples. 
3. Figure 5F. Can labels more informative than "Stromal 1", "Stromal 2" be provided, without having to 
refer to supplementary materials. 
4. Supp Figure H: were pediatric samples tested here for comparison? 
5. The SARS-Cov19 data (ACE2, TRMPSS) is quite interesting and important, but sensitivities with respect 
to stem cell infections in utero should be considered. 
6. Line 180: Given the absence of third trimester data, it is a bit misleading to say that Paneth cells 
appear post-natally. 
7. Line 257: DLL3 (vs. DDL3) typographical error? 


























































Author Rebuttals to Initial Comments: 
 
 
We thank the editor and reviewers for their time in considering our manuscript. In response 
to the reviewers’ comments, we have performed additional analyses, which we feel have 
substantially improved the manuscript. 
 
Additional work includes: 
1. Integration of additional fetal (donor n=2 and tissue samples n=5) and adult (donor 
n=2 and tissue samples n=22) single cell RNA sequencing data. 
2. 10x Genomics Visium spatial analysis of fetal intestinal tissues. 
3. Additional smFISH staining to validate ILC and neural cell populations and 
clarification of nomenclature of enteric nervous system cells. 
 
A point-by-point response to reviewers’ comments is detailed below. Additional text is 
highlighted in blue and revised changes are highlighted in red. 
 
Reviewer #1: 
1.1 Among the annotated epithelial clusters I 
did not see sub-clusters of SST and SCT 
expressing enteroendocrine cells. I would 
expect to observe these cells at least in 
the adult samples (not sure about the 
presence of these cells in fetal gut). In 
general, it would be good to annotate for 
which stages and which anatomical 
regions a given cell type can be 
observed. The authors should also 
explain in more detail how they arrived at 
the 103 cell types obtained by clustering. 
How did they determine which 
parameters to use for clustering (in 
particular, how were the resolution 
parameter and number of principal 
components selected)? Is the list of 103 
cell types likely to be complete or do the 
authors anticipate that further resolution- 
increase is likely to reveal additional 
distinct sub-types? 
We thank the reviewer for their constructive 
comments on the manuscript. 
 
After further inspection of enteroendocrine 
cells, we observe and annotate a SST+ 
enteroendocrine cluster corresponding to D 
cells (Figure R1) and include these results in 
the revised Figure 2e. SCT expression was 
observed across mature enteroendocrine 
clusters as well as in all fetal epithelial cells 
(Figure R2). 






















    
 
  
    
Figure R1: UMAP visualisation of EECs from 
fetal, pediatric and adult datasets with 




















Figure R2: Dotplots showing expression of 
EPCAM and SCT in the fetal and ped./adult 
epithelial subsets. 
 
As requested, we have also included a table 
with the summary of the number of cells in 
each stage and anatomical region for each 
cell type in the revised manuscript (Table 2). 
 
Identifying cell clusters in a single-cell 
experiment is challenging because there is 
no one correct clustering for any dataset, 
and no gold-standard way to select a single 
best clustering. Algorithms for inspecting 
and selecting resolution of clustering exist 
(e.g. Clustree), however with a large number 
of clusters, interpretation becomes difficult. 
 
We have chosen to annotate each sample 
group separately (fetal, pediatric and adult), 
choosing the best parameters within each 
group. In order to determine clustering 
parameters, we inspected the total variance 
of each cell lineage (epithelial, mesenchymal 
ect) by looking at top 50 PCs. We included 
up to 50 PCs depending on whether the 
resulting clustering revealed meaningful cell 
types. After annotation of each dataset 
separately, we then integrated the datasets 
together and inspected the clustering of 
annotated cells. The annotations were 
  manually adjusted based on clustering 
between datasets. 
 
We observed that some clusters, especially 
in the fetal dataset, represented 
differentiating subsets (e.g. pericytes) and 
avoided over-annotation in such cases. In 
addition, given the size of our dataset we are 
able to distinguish rare subsets of cells not 
detected in other single cell RNAseq 
datasets (e.g. enteroendocrine subsets, 
Microfold cells). However, it is also possible 
that not all cell types were captured in this 
data due to technical reasons (e.g. we did 
not capture adult enteric neurons due to 
difficult dissociation of neurons). 
 
We anticipate that further integration with 
new data modalities, such as scATAC-seq 
and spatial methods will reveal additional 
cell types and states beyond those currently 
described, especially in lineages with less 
well described cell types/states (e.g. 
mesenchymal subsets). 
1.2 The data shown in Figure 1F actually 
indicate expression of SCT in fetal 
enterocytes. I would expect to find 
expression of secretin only in hormone 
producing secretory cells. It is also not 
clear to me from the legend, if the dot 
plot highlights expression only for 
enterocytes or for all cells at the 
respective stage and region. 
Figure 1f shows the expression of selected 
marker genes across BEST4+ cells in 
different anatomical regions. We have now 
clarified this in the figure legend: 
 
“f) Dotplot with relative expression of 
selected marker genes within BEST4+ 
epithelial cells from small and large 
intestines and different ages.” 
 
Thank you for highlighting the SCT 
expression in fetal enterocytes. Secretin, 
encoded by the SCT gene, has been 
reported to be widely expressed in the 
mouse developing enterocytes 1. Similarly, 
we observe SCT gene expression across all 
epithelial subtypes of the developing human 
intestine (Figure R2). In adults, the SCT 
expression becomes restricted to the 
enteroendocrine lineage. 
1.3 When the authors describe their finding 
of BEST4+ enterocytes across human 
small and large intestine (line 133), they 
should also mention that these cells have 
been described across these regions 
before and cite the corresponding paper 
(Ito et al., ref. 54), which they mention in 
the discussion. 
Thank you, we have now included this 
reference (as ref. 11) in the results section 
as follows: 
 
“Notably, BEST4+ epithelial cells, previously 
observed in human small and large 
intestines 2 and predicted to transport metal 
ions and salts3,4, varied in abundance 
between intestinal regions <..>” 
1.4 In the discussion, the authors mention 
that BEST4+ enterocytes have only been 
described for the colon (line 554), and 
they cite ref. 54 (Ito et al.). However, the 
study clearly describes the presence of 
BEST4+ absorptive enterocytes in the 
small intestine and colon as well, in 
contrast to BEST2+ goblet cells, which 
were only found in the colon. Did the 
authors also look for differential presence 
of these BEST2+ goblet cells across life 
stages and tissues? 
We indeed find a subset of goblet cells that 
is specifically marked by BEST2 expression 
and is present in the large intestinal tissues 
(Figure R3a-b). We have now included these 
results in the revised Figure 2b and 
Supplementary 3g-i. 
 
Pediatric/adult BEST2+ cells clustered apart 
from BEST2- goblet cells (Figure R3c), but 
shared expression of goblet cell 
characteristic genes, including MUC2, 
CLCA1 and SPDEF (Figure R3d). Amongst 
the genes enriched in BEST2+ goblet cells 
were Kallikreins KLK15 and KLK3, as well 
as protease inhibitors WFDC2 and WFDC3 
(Figure R3d). However, the majority of the 
differentially expressed genes reflected their 
colonocyte or enterocyte identity (e.g. 
CD177 and LYPD8 were expressed in 
colonic goblet cells, while APOA1 and RBP2 
in small intestinal goblets; Figure R3e). 
 
Amongst fetal epithelial cells we found 43 
large intestinal cells that expressed BEST2 
(Figure R3f-g). Fetal BEST2-expressing 
cells clustered together with small intestinal 
cells (possibly due to the small number of 
these cells present in the data), but showed 
expression of genes defined using adult 










































































Figure R3: BEST2+ goblet cells in fetal and 
adult epithelial cells. a) Feature plots with 
expression of MUC2 (indicating goblet cells) 
and BEST2 in pediatric/adult epithelial cells. 
b) Barplot with number of goblet cells 
captured across intestinal tissues. c) UMAP 
visualisation of pediatric/adult epithelial 
subsets and their regional distribution. d) 
Dotplot with genes that correlate with BEST2 
expression calculated using Jaccard 
Similarity measure. e) UMAP visualisation of 
regional distribution of fetal epithelial cells. f) 
Feature plots with expression of MUC2 
(indicating goblet cells) and BEST2. Arrow 
points to 43 BEST2-expressing goblet cells. 
g) Dotplot of genes as in d) and additionally 
























1.5 It would be helpful to include a pathways 
enrichment or GSEA analysis in BEST4+ 
versus BEST4- enterocytes, and between 
BEST4+ cells found in small intestine 
versus colon. What is the function of 
these cells during homeostasis? 
We thank the reviewer for this suggestion. 
We ran GO term enrichment analysis on 
genes from Milo5 analysis of BEST4+ 
enterocytes from adult small versus large 
intestines and vice versa. Among GO terms 
for BEST4+ enterocytes of the adult small 
intestine are “Cotranslational protein 
targeting to membrane”, “Translation 
initiation”, “Viral gene expression” and 
biosynthesis of organic acid, monocarboxylic 
acid and fatty acid (Figure R4; top). In the 
large intestines these cells upregulated 
genes associated with “Response to oxygen 
levels”, “Cellular carbohydrate metabolism 
process”, “ATP metabolic process”, “Purine 
containing compound metabolic process” 
and transport of inorganic anion, chloride 
and sodium ion (Figure R4; bottom). These 
terms suggest a major functional difference 
of these cells between intestinal regions is 
biosynthesis of acids in the small intestines 
versus metabolism of small molecules in the 
large intestine. We include this analysis in 
Supplementary Fig. 3f and highlight these 
findings in the text of the revised manuscript 
and here for your convenience: 
 
“Gene ontology term enrichment analysis of 
genes differentially expressed by BEST4+ 
cells between adult small and large 
intestines suggests that further major 
distinction in the function of these cells is 
biosynthesis of acids and metabolism of 
small molecules, respectively 
(Supplementary Fig. 3f).” 




Figure R4: Gene ontology terms from genes 
upregulated in BEST4+ enterocytes from 
adult small (top) versus large (bottom) 
intestines as determined by Milo analysis. 
1.6 CFTR expression in epithelial cells could 
be relevant for mucus production by 
nearby goblet cells, for instance, by 
hydrating the mucus layer, and avoiding 
organ obstruction by a thick mucus layer, 
which could represent a first step of 
inflammatory disease. It would be 
interesting to investigate co-localization 
of BEST4+ cells with goblet cells. Could 
these cells have a specific role in aiding 
mucus production by goblet cells? 
We appreciate this suggested link between 
BEST4+ enterocytes and goblet cells for 
hydrating the mucus layer of the intestines. 
We would like to highlight findings by Ito and 
colleagues in PLOS 2013  figure 1C, in 
which Best4+ cells are visualised next to 
cells with a goblet cell morphology. In 
addition, we show examples of such co- 
occurrence in images from Protein Cell Atlas 
(Figure R5). 
 
We have now referenced this in the revised 
manuscript and below: 
 
“Interestingly, small intestinal BEST4+ cells 
were marked by high expression of chloride 
channel and cystic fibrosis gene CFTR 
(Figure 1f), which we also observed at the 







  Previous work has placed BEST4+ cells in 
close proximity to cells resembling goblet 
cells2. This highlights a possible role of 
BEST4+ enterocytes in aiding mucus 
production by goblet cells specifically in the 
small intestines.” 
 
   
 
   
Figure R5: Proximity of goblet and BEST4+ 
cells in the human small intestine. IHC 
staining of BEST4 and CFTR in small 
intestinal sections (proteincellatlas.org). 
Black arrows point to cells with goblet cell 
morphology and red arrows point to cells 
expressing either BEST4 or CFTR. 
1.7 Is it possible to derive EEC differentiation 
trajectories from NEUROG3+ enriched in 
samples of the first trimester towards the 
different mature sub-types observed 
starting from the second trimester? Could 
the authors predict which pathways 
trigger maturation of this lineage between 
the two developmental stages? 
Subclustering of EECs revealed 
NEUROG3+ precursor cells and multiple 
mature subsets resembling populations 
recently described in intestinal organoid 
experiments, including M/X cells 
(MLN/GHRL+), D cells (SST+), L cells 
(GCG+), N cells (NTS+), K cells (GIP+), I 
cells (CCK+) and enterochromaffin (EC) 
cells (TPH1+) either expressing 
Neuropeptide W (NPW+) or TAC1+ (Figure 
R1 above and R6). 
 
NEUROG3+ progenitors were enriched in 
the first trimester, while hormone expressing 
subsets were instead enriched in the second 
trimester samples (Figure R1). In addition, 
we capture a small subset of insulin 
expressing β cells (INS+) in the first trimester 
proximal intestinal gut, possibly contaminating 
from developing pancreatic bud (Figure R1). 
 
  While NPW expression is known to stimulate 
food intake 6 and observed to be broadly 
expressed by EECs 7,8, here we observe a 
specific subpopulation of NPW+ ECs marked 
also by expression of PRAC1 and FXYD2 
(Figure R6a-b). 
 
We further delineate genes involved in the 
differentiation of EC cells from NEUROG3+ 
precursors (Figure R6c). These genes 
included known transcription factors such as 
NEUROD1, CHGB, CHGB, PAX4 and PAX6, 
as well as recently described genes such as 
FEV 9,10. Finally, we use proteincellatlas.org 
images to visualise some of these genes, 
including KLK12 and AFP, that were found in 
NEUROG3+ progenitors and were located at 
the bottom of the crypts. Other identified 
genes marked specific subsets of intestinal 
cells (Figure R6d). 
 
We have now summarised these results in 
the revised Figure 2e-g (Supplementary Fig. 
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Figure R6: a) UMAP visualisation of EECs 
from fetal, pediatric and adult datasets, 
where arrows depict differentiation paths 
 
  inferred from scVelo analysis. b) Feature 
plots showing key genes of NPW+ 
enterochromaffin (EC) cells. c) Heatmap 
with genes that change along the 
differentiation trajectory from NEROG3+ 
progenitors to EC cells as highlighted by red 
arrow in a). Arrows indicate known genes 
associated with EC differentiation in mice 
and organoids. d) Immunohistochemical 
staining of selected genes from c) in the 
small intestinal sections from Human Protein 
Atlas (proteinatlas.org). Arrows point to 
positive cells. 
1.8 The authors hypothesize that IgG 
sensing of tuft cells via FCGR2A 
activates PLCG2 and may affect the 
inflammatory response of the gut. Is there 
any evidence for a physiological role of 
PLCG2 in the context of inflammation. To 
complement the organoid experiment it 
would be informative to test whether this 
gene (and also Fcgr3) is up-regulated 
upon treatment of mice with inflammatory 
cytokines or in IBD mouse models (using 
data from published studies). With regard 
to the organoid experiments the authors 
should address whether up-regulation of 
PLCG2 is due to increased expression in 
tuft cells or other cell types, and whether 
FCGR2A also increases in expression 
upon treatment with inflammatory 
cytokines in tuft cells specifically. 
Thank you for insightful comments regarding 
the PLCG2 role in inflammation. 
 
Activated PLCG2 is involved in inflammatory 
responses in immune cells triggered by 
receptors such as FCGR2A. In neutrophils 
PLCG2 downstream of Fc receptor- 
mediated and integrin signalling is required 
for degranulation and adhesion/spreading in 
inflamed capillary venules 11. Furthermore, 
gain-of-function mutation in murine PLCG2 
has been shown to result in hyperreactive 
external calcium entry in B cells and 
expansion of innate inflammatory cells 12. 
Other receptor types, via cross-talks, are 
also implicated, but the links are less-well 
documented. 
 
In addition, we now show a significant 
increase in inhibitory FcγRIIb-expressing tuft 
cells in DSS colitis mice (Figure R7). 
   
 
Figure R7: Percent expression of indicated 
Fcү receptors by SiglecF+EpCAM+ small 
intestinal tuft cells in wild type (n=5) and 
DSS treated (n=3) mice determined by flow 
cytometry. Mean with standard deviation is 
shown in bar plots, and statistics are 
calculated by multiple t-test analysis 
**=p<0.01; NS= non-significant. 
Based on feedback from each reviewer, we 
have decided to move mention of a role for 
tuft cells in IBD via PLCG2 to the discussion 
section and have included this section here 
for your convenience: 
 
“Since IgG can uniquely transverse the 
placenta, this provides a potential route for 
passive immunization and tuft cell activation 
in utero. Additionally, IgG in maternal breast 
milk may activate tuft cells in early life. Two 
missense variants of PLCG2 have been 
linked to aberrant B cell responses in early 
onset IBD (de Lange et al. 2017; Uhlig 2013) 
and primary immune deficiency (Martín- 
Nalda et al. 2020). It is possible that tuft 
cells, via PLCG2 signalling, could also 
contribute to IBD pathology and immune- 
related disease, a link that requires further 
investigation.” 
 
Regarding the organoid experiments in the 
original manuscript, PLCG2 expression is 
increased in all epithelial cells. During this 
experiment, the organoids were stimulated 
with cytokines in maintenance condition and 
we did not observe organoid-derived Tuft 
cells in this data (no expression of Tuft cell 
specific gene POU2F3) (Figure R8). We 
were unable to detect FCGR2A or FCGR2B 
expression by these organoids derived from 
control or Crohn’s pediatric samples and 
treated with inflammatory cytokines (Figure 
R8). These results are confounded again by 
the absence or low number of tuft cells 
detected in these samples, but suggest that 
epithelial PLCG2 can also be activated in 
the absence of Fcγ receptors. 
We clarify this in the text and here: 
“While there was no morphological 
difference in stimulated organoid lines and 
limited expression of FCGR2A 
(Supplementary Fig. 3F), we confirm an 
increase in PLCG2 expression across 
stimulated organoid epithelial cells 













Figure R8: Heatmap of normalised gene 
expression in single cell RNAseq data of 
organoids from Crohn’s (n=1) and control 
(n=3) pediatric biopsies stimulated with 
inflammatory cytokines. 
 
In addition, we have performed in vitro 
experiments in which we differentiate human 
intestinal organoids and see an increase in 
  Tuft cells as marked by POU2F3 expression 
as well as increased FCGR2A/B and PLCG2 
expression in differentiated cultures (Figure 
R9). These results support the presence of 
Fcγ receptor-expressing tuft cells in humans. 
These results are now summarised in the 




Figure R9: Morphology of undifferentiated 
(back) and differentiated (blue) intestinal 
organoids. Expression of LGR5 and MUC2, 
and other key genes by human intestinal 
organoids as determined by qPCR. 
1.9 Regarding the characterization of gut 
ILCs, I’m not convinced about the 
classification into ILC3s and ILCPs. I 
would expect up-regulation of KIT and 
ITGB7 in ILCPs versus mature ILC3s. I 
would also expect reduced levels of 
RORC in ILCPs versus mature ILC3s. 
The cells classified as ILC3s also have 
increased levels of ID2 compared to 
ILCPs and do not express IL17A which 
argues against their classification as 
mature cells. Since the cells classified as 
ILCPs up-regulate ZBTB16 and TCF7 I 
do believe that they could correspond to 
progenitors, however, I doubt the 
classification as mature ILC3s is correct 
for the respective cluster. Please also 
show additional progenitor markers from 
Lim et al. (2017) Cell, such as Cd7 and 
Il1r1. Do the ILCPs also express markers 
of ILC1s and ILC2, i.e., T-BET, CRTh2, 
and GATA3, at low levels? 
In response to the reviewer's comment, we 
provide human ILCP marker gene 
expression described by Lim et al. (Cell, 
2017) (Figure R10a). However, we note that 
this study describes ILCPs in peripheral 
blood (PB) and suggests that PB ILCPs are 
dramatically different from the equivalent 
cells in the adult gut. The majority of marker 
genes described in human PB ILCPs were 
expressed across gut ILC subsets (Figure 
R10a). 
 
Lim et al. further point to differences in 
ILCPs of tissue versus PB and classify fetal 
liver ILCPs as LinCD127+ (IL7R), CD117+ 
(KIT), RORC+ cells that further express 
CCR6, neuropilin-1 (NRP1), but not NKp44 
(NCR2). Fetal liver ILCPs also did not 
produce significant amounts of IL-17A or IL- 
22. Our ILCP cells best fit the above 
description of fetal liver ILCPs as described 
in Lim et al., Cell (2017) (Figure R10a). 
 
In addition, we directly compare 
transcriptional signatures of our gut ILC 
subsets and the human fetal liver ILC 
  progenitors described in Popescu et al., 
Nature 2019 (Figure R10b). Along with other 
genes characteristic of intestinal ILCPs, we 
note high expression of SCN1B and HPN 
that we also observe in liver ILCPs. These 
cells might be the first migrants from the 
fetal liver to gut. To visualise SCN1B+ ILCPs 
in the fetal gut, we use smFISH imaging and 
show the presence of all three LTi-like 
populations described in our study (Figure 
R10c). 
 
Regarding ILC3 maturity, we observed the 
expression of IL22 in the adult compared to 
fetal NRC2+ ILC3 (Figure R10a), suggesting 
that fetal gut ILC3 represents an immature 
ILC3 counterpart. We use “mature ILC3” 
nomenclature when describing adult ILC3s 
in the revised manuscript: 
 
“The second cluster labelled ‘LTi-like NCR+ 
ILC3’ clustered closely with mature ILC3 
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Figure R10: a) Dotplot with expression of 
genes described in peripheral ILCPs and 
fetal liver CD177+ ILCPs by Lim et al. (Cell, 
2017). In addition, we show the expression 
of ILC1 and ILC2 markers and selected 
cytokines. b) Dotplot with scaled expression 
of ILC3 and ILCP markers in fetal liver 
ILCPs from Popescu et al., Nature 2019 and 
LTi-like subsets described in this study. c) 
smFISH imaging of ILCP (SCN1B+), LTi-like 
NCR- ILC3 (IL17A+) and LTi-like NCR+ 




We would like to further note that after 
inspection of G D chain expression if the 
smart-seq2 data, we did not find TCRαb or 
TCRγδ chains in the cells previously named 
“LTi-like NK/T” (Figure R11b). Based on 
RORC and KIT expression and similarity of 
these cells to the adult Th17 subset, we 
have decided to revise their annotation to 
“NCR- ILC3”. The expression of IL17 by this 
subset is consistent with ILC3 cells 
described in mouse 13. 
 
These results are now included in the main 
Figures 4 and 5 as well as Supplementary 
Fig. 7. 
 




































Figure R11: a) UMAP visualization of T and 
innate-like cells in fetal, pediatric and adult 
samples. Dotted line denotes lymphoid 
tissue inducer (LTi)-like cell types. “ILC3” 
refers to the adult subset. b) Barplot showing 
TRACER analysis of TCR chains in cells 
captured using full-length Smart-seq2 single 
cell sequencing. c) Heatmap showing mean 


































































  fetal and Crohn’s disease stromal and 
immune cell populations. 
1.10 What is the meaning of the arrows in the 
UMAP of Figure 2? I could not find a 
description in the legend. 
The arrows in Figure 2a depict the inferred 
paths of differentiation from epithelial 
progenitor and crypt cells towards secretory 
and absorptive enterocytes. 
 
We have now removed these arrows in the 
revised figure and replaced these with 
arrows determined from RNA velocity 
analysis to show the developmental 
relationship between epithelial cell types. 
This figure is included as Figure 2a-b with a 




Figure R12: UMAP of epithelial cell types 
detected in single cell RNAseq dataset of (a) 
fetal small and large intestine and (b) pooled 
pediatric and adult intestinal samples. RNA 
velocity analysis is overlaid on UMAP. 
1.11 The description of the Milo method is too 
superficial. It is unclear to me how the 
authors control for overall differences in 
numbers and relative abundances (which 
might be of technical nature) between 
samples in integrated datasets analysed 
with Milo and how exactly they test for 
differential abundance statistically. 
In short, Milo method performs differential 
abundance testing by assigning cells to 
partially overlapping neighbourhoods on a k- 
nearest neighbour graph. The variability in 
the number of cells between samples is 
modelled using a generalized linear model, 
and the total number of cells in each sample 
is used as an offset. Further detail about the 
Milo method can also be found in a recent 




2.1 Elmentaite and colleagues report here a 
vastly comprehensive catalogue of cells 
and single cell gene expression patterns, 
throughout different intestinal tissues and 
human age. This is an impressive 
catalogue (a word used by the authors), 
which the authors use to map cells 
involved in pathologies, such as IBD and 
Hirschsprung’s disease. They also use 
this database to identify pathways that 
regulate Tuft cells and type 2 immunity, 
and the LTi-LTo crosstalk required for the 
development of lymphoid tissues during 
ontogeny and chronic inflammatory 
pathology. 
 
In my particular field of expertise, 
immunology and the development of 
lymphoid tissues, the biology developed 
in the manuscript is precise and correct, 
and the interpretation of the data largely 
confirms previous knowledge. I have to 
confess that it is however extremely 
difficult, for me, to have a critical 
appreciation of the data, which consists 
mainly of scRNAseq data treatment. 
Therefore, given the correctness of the 
interpretation, and my inability to judge 
the quality of the data, I cannot manage 
to propose sensible revisions. 
 
In sum, this manuscript is impressive in 
its scope and quantity of data, 
interpretation pertaining to my area of 
expertise is correct, but net advancement 
in knowledge is limited. This study will 
nevertheless provide the field with an 
invaluable resource. 
We thank the reviewer for their time in 
reviewing our manuscript and for 
appreciating its scope and accuracy in 
interpretation. We also believe that this 
manuscript and dataset will be of great value 
to the field. 
 
In particular, we are excited by the following 
key features of our manuscript: 
 
● The most comprehensive single-cell 
census of healthy human intestines 
covering in utero development, 
childhood and adulthood, and 
encompassing approximately 350,000 
cells from 27 donors and up to 10 
anatomical regions. 
● A systems integrated analysis approach 
leading to characterisation and first 
human description of three key cell 
players driving gut-associated lymphoid 
tissue formation in development: cells of 
mesenchymal, endothelial and lymphoid 
origin, and adaptation of this cellular 
program for immune cell recruitment in 
pediatric Crohn’s disease 
● Novel identification of IgG sensing by 
tuft cells. 
● Novel enteric neuronal progenitors, and 
cell type-specific expression of 
Hirschsprung’s disease- risk genes in a 
neuromuscular cell circuitry. 
 
Referee #3: 
3.1 The manuscript by Elmentaite et al 
provides a new human gut cell atlas 
encompassing single cell RNA- 
sequencing analysis of fetal, pediatric 
and adult cell populations. 350 000 high- 
We thank the reviewer for their positive 
outlook of our manuscript and valuable 
suggestions. 
 
With regards to how our manuscript 
 quality intestinal cells are included 
representing various gut cell types at 
distinct anatomical positions. The 
presentation focuses on 1) the epithelial 
compartment, highlighting distinct 
BEST4+ in small intestine versus colon 
and proposing tuft cells in the 
pathogenesis of IBD by IgG sensing 2) 
the gradual differentiation of ENS from 
ENCCs, highlighting presence of many 
glial populations and interactions with 
claimed relevance for Hirschsprung’s 
disease 3) genetic programs controlling 
lymphoid structure formation, highlighting 
its reactivation during pediatric Crohn’s 
disease. 
 
The study forms a valuable resource for a 
vast range of intestinal research and 
gives an impressive description of the 
gradual development and maturation of 
the human intestine including associated 
mesenteric lymph nodes. However, as a 
whole, the manuscript represents a 
patchwork of topics, each alone with 
limited depth sometimes suffering from 
far-fetched conclusions. The manuscript 
would be much improved if the data-sets 
would be presented as a resource and 
speculative aspects moved to the 
discussion. It will important to justify how 
your atlas stands out and compares to 
the many recent publications describing 
the developing and adult gut by RNA-seq 
(see also major issue 4; e.g. Fawkner- 
Corbett et al., Cell 2021; Han et al., 
Nature 2020; Holloway et al., Cell Stem 
Cells, 2020; Cao et al. Science 2020). 
Alternatively the manuscript could be split 
- several impactful studies (up to 3) could 
potentially be made by following up each 
part with functional experiments. 
compares to the studies published to date, 
we include Table R1, summarising the 
samples and cell types described previously 
and in the present study. 
 
In summary, we present the most in-depth 
sampling of the adult human gut, with single- 
cell transcriptomes from up to 12 distinct 
regions along the intestinal tract from 
disease transplant donors, in contrast to 
other published datasets where biopsies 
were used. 
 
In addition, we include transcriptomes from 
the developing mesenteric lymph nodes as 
well as their counterparts from the adult, and 
in doing so provide an in-depth catalogue of 
immune cells that survey the adult and 
developing gut. 
 
Through careful scholarship, analysis and 
interpretation of this data, we have provided 
unprecedented insights (i.e. Tuft immune 
sensing, enteroendocrine differentiation, 
lymphoid tissue formation, and timepoints 
and locations of ENS differentiation) and 
contextualised these with other single cell 
studies (i.e. BEST4+ 
enterocytes/colonocytes, comparable 
branching of ENS development in mice and 
humans). 
3.2 Major Issues: 
1) Presence of small intestine BEST4+ 
cells is claimed as a novel finding in the 
abstract and introduction, although 
We clarify this in abstract: 
 
“This reveals the presence of BEST4+ 
absorptive cells throughout the human 
 BEST4+ cells have previously been 
reported across the human intestine 
including both small intestine and colon 
with regular immunohistochemistry (Ito et 
al., 2013 PLoS One). The present 
manuscript describes however a very 
interesting regional difference between 
the BEST4+ cells that are appropriate to 
high-light. Please rephrase the major 
finding in the abstract and introduction 
(perhaps focusing instead of the 
transcriptional difference between 
BEST4+ cells in colon and small 
intestine?). 
intestinal tract, demonstrating the existence 
of transcriptionally distinct BEST4+ cells 




“In doing so, we reveal new insights into the 
epithelial compartment: we identify 
transcriptional differences between the 
BEST4+ cells in the small and large intestine 
<..>”. 
3.3 2) PLCG2 expressing Tuft-cells: 
a) The presumed link between IgG 
sensing Tuft cells and IBD are built on 
several assumptions forming 
circumstantial reasoning. For many IBD 
risk genes, the cells in which the gene 
acts has not been established. In the 
case of Plcg2, an obvious role within the 
immune system is shown. It is possible 
that the small proportion of Tuft cells are 
IgG sensing via Plcg2 and could 
contribute to disease, but convincing 
evidence are lacking herein. What is the 
evidence for that Fcgr2a can upregulate 
Plcg2? Is Fcgr2a expression increased in 
CD patients material? The suggested link 
is to this reviewer too weak to be high- 
lighted in the results section. It would be 
more appropriate to more generally 
suggest signaling pathways involved in 
the immunological responses of Tuft 
cells, where Plcg2 could be one plausible 
gene. The possible role in IBD belongs to 
the discussion. 
Thank you, we agree that the link between 
IgG sensing by tuft cells and IBD is not 
substantially supported and we have moved 
comments about this to the discussion as 
suggested (please also refer to comment 1.8 
for further information). 
 
We have also used the finding of FCGR2A 
expression by tuft cells as an example more 
generally of the ability of tuft cells to engage 
in immune signalling. The relevant text from 
the manuscript is included below in blue. 
With regards to whether FCGR2A can 
upregulate PLCG2, there is considerable 
background data that FCGR2A is a receptor 
that activates PLCG2 and that one receptor 
is able to activate many PLC molecules. 
However, to our knowledge there is no data 
about the upregulation of PLCG2 in 
response to FCGR2a signalling. 
Furthermore, we cannot see expression of 
FCGR2A in our organoid cultures derived 
from pediatric Crohn’s and control samples 
(Figure R8 above and again below). The 
clear evidence presented in this manuscript 
that PLCg2 is expressed at higher levels in 
Turf cells compared to other cell types (the 
finding not previously appreciated) will have 
considerable impact on many studies in the 
field. In particular, IBD- linked variants of 
PLCG2 will need to be assessed in the 
context of this cell type. 
   
“We discover that FCGR2A, a receptor 
activated by the Fc fragment of IgG upstream 
of PLCG2, and other downstream signaling 
molecules are expressed by tuft cells. Since 
IgG can uniquely transverse the placenta, this 
provides a potential route for passive 
immunization and tuft cell activation in utero. 
Additionally, IgG in maternal breast milk may 
activate tuft cells in early life. Two missense 
variants of PLCG2 have been linked to 
aberrant B cell responses in early onset IBD 
14,15 and primary immune deficiency 16. It is 
possible that tuft cells, via PLCG2 signalling, 
could also contribute to IBD pathology and 
immune-related disease, a link that requires 
further investigation. Overall, this data 
suggests a novel and potentially very 




Figure R8: Heatmap of normalised gene 
expression in single cell RNAseq data of 
organoids from Crohn’s (n=1) and control 
(n=3) pediatric biopsies stimulated with 
inflammatory cytokines. 
3.4 b) The presumed receptor activating 
Plcg2 is expressed in a very small 
proportion of Tuft cells (2,5%). Despite 
this, organoid cells upregulate PLCG2 
upon TFNFa or IFNg treatment. Do you 
also observe an upregulation of Fcgr3 (or 
other ITAM receptor) following the 
treatment that could help boost the 
There was no observable expression of 
FCGR2A, FCRGR3 and other ITAM 
receptors in the organoid (Figure R8 above) 
or in pediatric Crohn’s and control single cell 
data. Additionally, FCGR3 is not upregulated 
by intestinal organoids following cytokine 
treatment (Figure R13). These results may, 
however, be confounded by the few tuft cells 
captured in these datasets. Thank you for 
 presumed signaling pathway? Similarily, 
is the receptor increased in CD patients? 
 
The lead is interesting, consider to 
continue this project to substantialize the 
findings and separate this part into an 
own manuscript. 
suggesting pursuing in a dedicated follow-up 








































Figure R13: Heatmap showing mean 
expression of selected receptors by 
intestinal organoids stimulated by TNFα, 
IFNy or control culture medium and 
processed by single-cell RNAseq. 
 
3.5 3) Analysis of the developing ENS has 
several issues that need to be 
addressed. 
 
a) Overall Analysis: The ENS develops 
through a protracted time period and 
neuron subtype specification appears to 
depend on time of birth (Pham et al J, 
Comp Neurol. 1991, Bergner et al. J 
Comp Neurol 2014) as well as post- 
mitotic neuronal conversions in mouse 
(Morarach et al, 2021 Nat.Neuroscience). 
Additionally, it is likely that the enteric 
progenitor population develops with time 
in analogy to the gradual differentiation of 
neural tube progenitors to “radial glia” 
phenotype in the CNS, upon which Blbp 
amongst others markers are increase in 
expression. Moreover, submucosal 
plexus only starts to be generated by 
W12-14 and colonic ENS will partly 
consist of sacral neural crest, likely 
having a different expression profile 
compared to the vagal neural crest 
progenitors. Thus, to be able to 
investigate discrete differentiation 
processes, regional and temporally 
different data-sets will need to be 
analysed in separation from one another. 
It appears as if the vast majority of 
the analysis is performed with cells 
merged from the whole neurogenic 
period at all regions (thus a span of 77 
days!). While an overall view with all 
stages should be shown and is 
informative, a detailed analysis of 
gliogenesis, neurogenesis and neuronal 
specification is likely hampered by 
inclusion of all stages/regions. A 
separation of for instance W6-10; W10- 
14 and W14-17 by the region would likely 
give better basis to clearly follow 
differentiation and branching events. This 
suggestion might resolve some of the 
specific issues identified below: 
Many thanks for the expert insights into ENS 
development. 
 
After separating the samples into multiple 
time point bins as suggested, we observed 
that cells from 6-11pcw and 12-17pcw 
displayed different differentiation trajectories, 
as predicted by the reviewer. We now 
include these results in the revised Figure 
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Figure R14: UMAP projection of enteric 
neural crest cell progenitors (ENCC) and 
their progeny at a) 6-11 pcw and b) 12- 
17pcw timepoints. The overlaid arrows show 
scVelo derived differentiation trajectory. 
Selected marker genes are listed for each 
 
population. c) Barplot with relative 
abundance (percentage %) of cell types 
amongst ENCC-lineage populations as 
described in a) and b) across intestinal 
regions and developmental timepoints. 
 
 
Overall, we did not observe major regional 
differences between neural cells- similar 
trajectories were observed when colonic 
ENS cells were subclustered (Figure R15). 
 
 


























Figure R15: UMAP visualisation of colonic 
neural cells colored by cell type annotation, 
sample, 10x Genomics technology version 
as well as key marker genes in the 
developing colon at a) 6-11pcw and b) 12- 
17pcw. 
 
To delineate the sacral versus vagal origin of 
neural subsets, we examined HOX gene 
expression patterns in the neuronal subsets 
from 6-11pcw samples, as suggested by the 
  reviewer (Figure R16). We observe low 
expression of anterior Hox genes in the Glia 
1 (DHH+) subset of cells, along with 
expression of posterior Hox genes in colonic 
Glia 1 (DHH+) subset. This suggests that 
colonic Glia 1 (DHH+) subset may have 
sacral origin. In addition, colonic Glia 1 
(DHH+) subset expressed POU3F3, specific 
to colonic neurons and uniquely expressed 
TFAP2B, which was not observed in 
equivalent cells from the small intestinal 
regions (Figure R16, genes in red). 
 
We now include this analysis in 
Supplementary Fig 5 and discuss this in text 
of the revised manuscript: 
 
“HOX gene expression further showed that 
colonic glia 1 cells expressed posterior HOX 
genes as well as TFAP2B, suggesting their 
sacral/trunk origin (Supplementary Fig. 5g- 
h).” 
 
anterior HOX genes posterior HOX genes 
 
 
Figure R16: HOX gene expression across 
developing neural subsets in 6-11pcw 
samples. FPIL= fetal proximal ileum, FTIL= 
fetal terminal ileum, FLI=fetal large intestine. 
Highlighted in red square are Glia 1 (DHH+) 
cells from all regions. Genes highlighted in 
red are colon specific. 
3.6 b) Committed glial precursors: It is not 
trivial to discern glial committed 
precursors from ENCCs or differentiated 
enteric glia. Higher levels of markers 
associated with adult glia would not 
To clarify, we score the progenitor/glial 
populations using literature curated gene list 
from Lasrado et al., Science (2017) (namely 
ERBB3, PLP1, COL18A1, SOX10, GAS7, 
FABP7, NID1, QKI, SPARC, MEST, 
 necessary indicate glial-committed 
precursors (could also indicate a more 
mature progenitor population that is still 
bi-potent). It is not clear which genes are 
used to define committed enteric glia. If it 
is those specified in methods part 
(Sox10, Mpz, S100b, Erbb3, Plp1, Gas7, 
Col18a1), please refer to appropriate 
confirming paper or propose a reasoning 
to picking these genes. The mentioned 
markers for this population (AGRM and 
SGO2) are also un-suggestive to mark 
glial committed precursors. AGRM is a 
known marker of radial glia that are 
multipotent (Marinaro et al., 2011 PLos 
One) and SGO2 has been shown to 
regulate mitosis (Gomez et al., EMBO 
Rep 2007). The expression of CCNA2 
and CCNB1 also points to that this 
population corresponds to a specific 
stage during the cell cycle. A committed 
glial precursor population would show all 
phases of the cell cycle – is that the 
case? Moreover, your data indicate a 
higher proportion of committed glia 
precursors at early stages (Figure 4B), 
while it is known that neuron 
differentiation proceeds glial 
differentiation in the developing ENS 
(although it is much more simultaneous 
than in the developing CNS). As 
suggested above, separation of data by 
stage (and perhaps region) would make 
the interpretation easier. 
WWTR1, GPM6B, RASA3, FLRT1, 
ITPRIPL1, ITGA4, POSTN, PDPN, NRCAM, 
TSPAN18, RGCC, LAMA4, PTPRZ1, 
HMGA2, TGFB2, ITGA6, SOX5, MTAP, 
HEYL, GPR17, TTYH1). We have clarified 
this in the Methods section. 
 
Regarding committed glial progenitors, we 
observed that this population is composed of 
G2M phase only and refer to it as “cycling 
glia/progenitor cells” in the revised 
manuscript and Figure R14 (above). 
 
Separation of the timepoints also allowed us 
to further clarify the timing of glia versus 
neuron differentiation in the human gut. In 6- 
11pcw, the most abundant population was 
ENS progenitors and only a small cluster of 
“Glia 1 (DHH+)” cells were observed at this 
time point (Figure R14a, c). The trajectory 
analysis suggests that at this time point, 
most of the ENS progenitors differentiate 
into enteric neurons via neuroblasts (Figure 
R14a). 
 
In 12-17pcw, we observed differentiation of 
the ENS progenitors to both glial and 
neuronal types (Figure R14b). At this 
timepoint, ENS progenitors appeared to give 
rise to three types of glial populations 
(Figure R14b). Firstly, via a branching event 
progenitors differentiate to DHH+ Glia 1 and 
ELN+ Glia 2 populations via differentiating 
glia. Secondly, progenitors differentiate to 
BCAN+ Glia 3 population (previously named 
Enteric Glia). 
 
We comment on this differentiation in the 
text of the revised manuscript: 
 
“While differentiated neuronal cells were 
abundant at 6-11PCW, glial cell types were 
enriched in the second time point (12- 
17PCW) suggesting that neuronal 
differentiation precedes gliogenesis. All 
terminal glial cells expressed high levels of 
ENCC progenitor/terminal glial marker 
  genes including FOXD3, MPZ, CDH19, 
PLP1, SOX10, S100B and ERBB3, but 
lacked RET (Supplementary Fig. 5f). We 
further observe three types of enteric glia: 
glia 1 (DHH, RXRG, NTRK2, SBSPON, 
MBP), glia 2 (ELN, TFAP2A, SOX8, 
BMP8B), glia 3 (BCAN, APOE, CALCA, 
HES5, FRZB) and a subset of differentiating 
glia (COL20A1) present in 12-17PCW. HOX 
gene expression further showed that colonic 
glia 1 cells expressed posterior HOX genes 
as well as TFAP2B, suggesting their 
sacral/trunk origin (Supplementary Fig. 5g- 
h). We visualised BMP8B+ cells in the 
myenteric plexus, while DHH+ cells were 
found both in the mesentery and myenteric 
plexus (Figure 3c, Supplementary Fig. 5i). “ 
3.7 c) Committed neuronal precursor: From 
the Velocity analysis these cells are 
probably committed to becoming 
neurons, going through their last cell- 
cycle, ie neurogenic. Would it be better to 
call them neuroblasts or neurogenic 
cells? These cells are expected to 
transiently express proneural genes such 
as higher ASCL1 while downregulating 
progenitor genes (Sox10, Sox2) and 
upregulating early neuronal genes 
(Tubb2, Pgp9.5, Elavl4). The neurogenic 
population has been defined in murine 
ENS (Morarach et al., Nat. Neurosci 
2021) and it could be useful to utilize this 
information to annotate the human 
neurogenic phase (although of course 
some gene are likely to differ, the 
majority of genes are probably 
conserved). For instance, Mfng, Dll1, Dll3 
are also markers of murine neuroblasts. 
We agree with the reviewer’s suggestion, 
and have changed our classification of 
“committed neuronal precursors” to 
“Neuroblast”. In Figure R17 we shown that 
the neuroblast bridge upregulates 
expression of ASCL1, ELAVL4, TUBB2B 
(but not UCHL1 (Pgp9.5)), and 
downregulates SOX10 and SOX2, fitting 
with their identity as neuroblasts. 
   
 
Figure R17: Feature plots with genes 
upregulated and downregulated in 
neuroblasts at 6-11 pcw. 
3.8 d) Annotation of Enteric Neuron 
Subtypes: The branches and logic of 
enteric neuron diversification in the 
mouse have recently been defined 
(Morarach et al Nat. Neurosci 2021). At 
neurogenesis, a binary event separates 
Etv1+ precursors (Branch A) from Bnc2+ 
precursors (Branch B), thus the same 
transcription factors observed in your 
human dataset. Branch A differentiate 
into Enteric Neuron Classes (ENC) 8-12 
– corresponding to inhibitory 
motorneurons (Nos1/Gal/Vip), Neurod6+ 
putative interneurons as well as 
Ntng1/Nxph2 neurons that possibly could 
be a mix between atypical IPANs and 
interneurons. Branch B differentiate into 
We have updated our neuron annotations 
based on reviewer’s comments and mouse 
data described in (Morarach et al Nat. 
Neurosci 2021), paying particular attention 
to division of branches (Figure R14a,b). 
 
In particular, we have labelled Branch A and 
B based on the expression of ETV1 and 
BNC2/DLX5 respectively (Figure R18a). In 
the UMAP of samples from 6-11pcw, Branch 
A co-expressed NOS1/GAL/VIP (inhibitory 
motor neurons; iMN) and further 
differentiated into NTNG1/NXPH2+ cells 
(IPAN). We did not observe the NEUROD6 
expression at this stage (Figure R18a). 
We also show a population of cells co- 
expressing PENK/TAC1/GRP at the end of 
 excitatory motorneurons (Penk+/Tac1+), 
IPANs (Nmu+, Dlx3+, Ano2+, Nog+, 
NTrk3+…), Interneuron/Intestinofugal 
Unc3/Cck cells and Sst+ putative 
interneurons. UMAP structure and 
Velocity analysis suggested that most 
neuron classes diverge at postmitotic 
stages by gradual conversions within the 
branches. Basic developmental 
processes are often conserved between 
species and authors could be helped to 
analyse their branching events and 
neuron types by consulting this 
framework in mouse. 
Branch A, suggestive of differentiation of 
excitatory motor (eMN) neurons from this 
lineage (Figure R18a). This observation is in 
contrast to differentiation of excitatory motor 
neurons only from Branch B as observed in 
mice. This population did not express 
FUT9/GDA as described in mature murine 
eMN (ENC1-4) by Morarach et al.,2021, 
suggesting these may be immature eMNs. In 
addition, we see a population of eMNs 
stemming from Branch B at 12-17pcw 
(Branch B (eMN)). The eMN populations 
differentiated from Branch A and B showed 
similar expression of marker genes (Figure 
R18a,b). This could suggest the possibility of 
human eMNs differentiating from both 

















Figure R18: Dotplots with expression of key 
genes used to define enteric neuron classes 
found at a) 6-11 pcw and b) 12-17pcw. 
Genes highlighted in red are discussed in 
text. Genes highlighted with black outline are 
expressed in eMN cells. 
 
Neuron differentiation observed at 12-17pcw 
was otherwise mostly consistent with 
observations in mice by Morarach et al., 
(Nat. Neurosci 2021). At this time point, we 
note further branching of Branch A to iMN 
(NOS1/GAL/VIP, Branch A (iMN)) as well as 
NEUROD6+ cells that are interneurons that 
reassemble murine ENC10. We did not 
observe UNC3/CCK expression suggestive 
of mature Interneuron/Intestinofugal cells. 
 
In addition, cells from 12-17pcw showed two 
 
  neuronal subclusters. Both subpopulations 
expressed BNC2, but not ETV1, suggesting 
they differentiated from Branch B. The first 
population as mentioned (Branch B (eMN)) 
above expressed genes observed in eMNs 
also seen at 6-11pcw including TAC1/PENK. 
The second population showed the 
expression consistent with IPANs including 
DLX3, ANO2, NOG and NTRK3 expression, 
and therefore labelled as “Branch B (IPAN)”. 
3.9 The current attempts to annotate 
neuronal subtype is partly questionable, 
relying solely on the recent un-validated 
annotation of enteric snRNA-seq clusters 
(Drokhlyansky, Cell 2020) ignoring a 
large body of literature already present 
used to identify enteric neuron subtypes. 
The Drokhlyansky atlas refer to all 
CGRP+ cells as sensory, although 
several other neuron populations express 
this marker, including the cholinergic 
secreto/vasodilatory neurons that were 
expected within that atlas but not 
annotated. The Drokhlyansky PSN1 is 
likely corresponding to IPANs, while 
PSN2-4 would need to be confirmed 
(these correspond to the murine ENC7, 
parts of ENC12 and likely cholinergic 
secretomotor/vasodilatory neurons). 
Consider to also consult May-Zhang et 
al., Gastroenterology for human IPAN 
characterization (both with RNA-seq and 
tissue staining). Please note that CGRP 
appears mainly transcribed from CALCB 
rather than CALCA in the ENS. 
To address this we have used the 
annotation consistent with Morarach et al., 
(Nat. Neurosci 2021) paper as described 
above. 
 
Based on the genes described in mature 
ENC1-12 classes, we could distinguish that 
Branch A iMN, resembled ENC8-9 (NOS1, 
GAL); Branch A NEUROD6+ INs resembled 
ENC10. Branch A IPAN/IN; resembled 
mature ENC12 (NTNG1, NXPH2) (Figure 
R18 a,b). 
 
Not all genes described in mature enteric 
neuron classes ENC1-12 were expressed in 
our populations (Figure R19). This could 
reflect species differences as well as 
differences in the sampled timepoints in our 
and mouse dataset (absence of 




ENC10, 5 ENC6-7, 12 ENC11 
 
Figure R19: Overlaid expression of genes 
described in ENC1-12 in Morarach et al., 
(Nat. Neurosci 2021). 
 
In our revised annotation, Branch B (IPAN) 
also showed expression of CALB2 and SST 
(Figure R20), described in human IPAN A 
population (May-Zhang et al., 
Gastroenterology). This further supported 
our annotation of this population as IPANs 
rather than PSN subsets. 
 
 
Figure R20: Dotplot with expression of IPAN 
A genes from (May-Zhang et al., 
Gastroenterology) in 12-17pcw neural 
populations. 
 
   
Finally, we visualise SCGN+ and BNC2+ 
enteric neurons in the adult tissue, 
supporting that these cells exist in post-natal 
gut tissue (Figure R21, bottom panels). 
 
 
Figure R21: smFISH imaging of BMP8B+ 
Glia 2 subtype and SCGN+/BNC2+ enteric 
neurons in the fetal (small intestine, 15pcw) 
and adult (55-60 years, terminal ileum). 
 
 
We have now added these results in the 
Supplementary Fig 5. 
3.10 For you annotation of possible enteric 
submucosal neurons, please note that 
this layer start to arise at around W12-14 
(Fu et al., 2004. Anat. Embryol 208:33- 
41.) -thus your stages W14-W17 should 
primarily be used to annotate these 
neuron types. The number of neurons at 
these older stages appear however 
limited, which might make such 
identification difficult. The markers you 
indicate (Vip, Etv1, Scgn and Unc5b) are 
also expressed in myenteric 
subpopulations, why caution should be 
taken to annotating submucosa based on 
these genes. Note that murine IPANs 
(ENC6) express Unc5b, while Scgn is 
expressed in murine ENC7 (mature 
markers CCK/Ucn3) and ENC10 
We have taken on board the reviewer’s 
suggestion to be cautious when 
discriminating between myenteric and 
submucosal enteric neurons in our data. 
 
To resolve the spatial distribution of 
neuronal and glial subsets in the developing 
human gut, we have generated and 
analysed 10x Visium spatial transcriptomics 
data on developing small intestinal regions 
from 13 and 17pcw gut. We use 
Cell2Location algorithm 17 to map the single- 
cell transcriptomes to the tissue zones 
(Methods). In this data, we observe the 
expected mapping of hallmark cell types, 
including enterocytes, intestinal stem cells 
























































(Neurod6+). Thus, with further 
investigation of murine datasets you may 
be able to link Branch 1 to ENC6/7 and 
Branch 2b to ENC10. An alternative to 
annotate cells by function is to refer to 
the Class number (Enteric Neuron 
Classes 1-12 in the mouse myenteric 
plexus). Future functional experiments 
will be needed to faithfully annotate 
the neuron clusters into functional 
classes. If you find enough similarity 
 
Regarding neuronal populations, we 
observed mapping of both neuronal 
branches to myenteric plexus (Figure R22b). 
However, the current 10x Genomics Visium 
chips at 50 micron resolution may not be 
able to discriminate between rare cell 
subsets. Further studies will be required to 
confidently map these populations in 
myentery versus submucosa. 
between murine and human neuronal 
a differentiation consider to use the same 




































3 3 10.0 
terminology as used in Morarach et al 
(Branch A, B; myenteric ENC1-12) for 































































































































































































































































































































































































































































































































































































































































































































































































































with associated mLN 
Figure R22: a) Spatial mapping of 
scRNAseq to Visium spatial transcriptomics 
sections of fetal tissue from 17pcw terminal 
ileum (top), 17pcw proximal ileum (middle) 
and 13pcw ileum (bottom). Cell abundance 
(colour intensity) of cell subsets (colour) is 
shown; b) Spatial cell abundance (colour 
intensity) of neuronal, smooth muscle and 
































Enterocyte Stem cells           ENS Prog/cycling 
 
0            7           14                  0.00       1.93       3.86                0.00       1.79       3.58 
SMC (PART1/CAPN3+)             mLTo 
 






























Enterocyte Stem cells                  ENS Progenitor 
 
0         6         13              0.00    4.17     8.33 0.00    1.26     2.52 
SMC (PART1/CAPN3+)                   mLTo 
 











































































































Regarding the reviewer’s suggestion to use 
consistent nomenclature, we use Branch 
  A/B nomenclature in our data and suggest 
neuron functional class by considering the 
gene expression suggested by the reviewer 
in comment 3.8. Since we do not observe 
convincing similarity between developing 
human enteric neurons and ENC classes 
described in adult mice, we refrain from 
using ENC classes in our annotations, but 
rather point to similar populations in text. 
Further direct comparisons between human 
and mouse datasets will be required to 
address similarities between mouse and 
human cells. 
3.11 e) Annotation of Glial classes: It is a hard 
to follow the annotation and reasoning for 
enteric glia and schwann cell-like 
clusters. All three schwann-cell like types 
are first defined as Schwann Cell 
Precursors (Row 268), while this term 
later in the text only denotes a subtype. It 
is also unclear why the markers PLP1, 
PMP22, CDH19 and ITGA4, CDH2 are 
used to define SCPs. No reference 
markers for human schwann cell 
precursors/cells that distinguish these 
from developing enteric glia has been 
published (if there is, please cite). All 
these markers are however robustly 
expressed within murine enteric glia (see: 
mousebrain.org – enteric glia, Zeisel et 
al., Cell 2018). Dhh is the only marker 
known to this reviewer that would 
faithfully distinguish schwann cell 
precursors from ENCCs (again this is 
from mouse studies including Uesaka et 
al., 2015). 
 
It would be advisable to re-think the 
nomenclature for the glial subtypes 
considering the following: 
Myelin SCP: Are you sure that 
myelinating Schwann cells are present in 
the mesentery and/or gut wall? 
Expression of Mpz is not a valid reason 
to call this a myelinating type as this is an 
early marker of schwann cells in general 
Thank you, we have now achieved a clearer 
differentiation trajectory by subsetting of the 
ENS data as described in point 3.6 above. 
 
“Myelin Schwann-like” cluster was enriched 
for MPZ, MAL, GFRA3 and DHH expression 
suggesting similarity to “putative SCP” found 
in mice (Morarach et al, 2021). To avoid 
confusion in the field we name this cell “Glia 
1 (DHH+)”. We also note that some DHH 
expression was observed within the gut wall 
in MPZ+ SOX10+ cells, but the expression 
of DHH was not as abundant as in the cells 
outside of the gut wall (Figure R23). In 
addition, DHH+ Glia 1 cells confidently 
mapped to tissue zones outside the gut wall 
in the spatial transcriptomics data (Figure 
R22b). Cells originally named as “SCP” 
clustered closely with DHH+ glial cells in 6- 
11pcw samples and we refer to this 
population as “Glia 1 (DHH+). 
 
 
Figure R23: smFISH imaging of DHH+ glial 










 (Jessen and Mirsky, 2019, Frontiers in 
Mol Neuroscience). This glial type could 
correspond to the (unvalidated) putative 
SCP found in mouse ENS (enriched Mpz, 
Mal, Wnt6, Gfra3 and Dhh; Morarach et 
al, 2021). Your validation of Dhh+ cells in 
mesentery (fig 3) does not rule out the 
presence of these cells within the gut 
wall, please re-analyse this possibility 
(given that Dhh+ cell in mouse infiltrate 
the gut wall and give rise to neurons at 
postnatal stages, Uesaka et al, 2015) 
 
Non-myelinating Schwann-like: What is 
the reasoning to denote this type 
schwann-like? The murine enteric glia 
consist of many subclasses (see Zeisel et 
al., 2018; mousebrain.org – enteric glia). 
These express variable levels of Eln, 
Sox8, Apoe, Bcan. Consider if your “non- 
myelin schwann-like cell” instead could 
correspond to a subdivision within the 
enteric glia. 
 
SCP: Please validate the presence of this 
cell type in tissue (as was performed with 
non-myelin Schwann cells with BMP8B). 
It is misleading to state enrichment in first 
trimester. These cells peak at W10 and 
are present with similar proportions at W9 
as w17. Stating the age of first detection 
would be more informative. 
 
In conclusion, considering no validation 
and functional analysis of glial 
populations, could they be annotated as 
enteric glia 1-4 in this atlas? 
 
Does the velocity and UMAP look more 
crisp if only relevant stages (W9-17) are 
included in the analysis of glial clusters 
and differentiation? 
 
Are the different glial populations 
regionally distributed (colon versus small 
intestine)? 
In the umap from combined timepoints, 
DHH+ glial cells from 6-11pcw and 12- 
17pcw samples clustered together (Figure 
R24a) and we further provide genes defining 
all three glia subsets (Figure R24b). As 
suggested by the reviewer, we annotate 
these subsets as Glia 1-3 and provide their 
defining genes in the brackets (Glia 1 
(DHH+), Glia 2 (ELN+), Glia 3 (BCAN+) and 
a subset of Differentiating glia (Figure 
R14b). 
 
Regarding regional distribution of glial 
populations, we observe all populations in 
both small and large fetal intestines (Figure 
R15 above and Figure R24c). 
 
c      Regional distribution          
 




















Figure R24: a) UMAP visualisation of neural 
subsets from 6-17pcw. b) Dotplot with genes 
defining each glial population. c) Barplot 
showing regional distribution of neural 
subsets in 6-17pcw timepoint. FPIL- fetal 
proximal ileum, FMIL- fetal middle ileum, 
FTIL- fetal terminal ileum, FLI- fetal large 
intestine. 
 
These results are now summarised in Figure 
3, Supplementary Fig. 5 as well as in section 
of the revised manuscript titled “Enteric 
nervous system differentiation during 
development”. 
 
3.12 f) Acknowledgement of present literature 
of the developing human ENS: Several of 
the identified signaling molecules have 
previously been investigated in the 
developing human ENS in an 
immunohistochemical atlas comparing 
murine and human ENS transcriptional 
and signaling regulators (Memic et al., 
Gastroenterology 2018). It would be 
appropriate to use this resource as 
validation for expression scRNA-seq. For 
instance, the mentioned GDF10 as well 
as other TGFB-receptors Tgfbr1, Tgfbr2 
and Tgfb2 protein expression have been 
detected at W6-10. The Branch 1 specific 
transcription factor Etv1 is also validated 
in human ENS within the same atlas. 
 
A very recent paper (Fawkner-Corbett et 
al., Cell 2021) also characterizes the 
developing human ENS (week 12-19), 
please refer to this paper and compare 
with your own analysis. 
We acknowledge work by Memic et al. in 
text as follows: 
 
“.. observed in developing human gut 
previously (Memic et al., Gastroenterology 
2018).“ 
 
We summarise general similarities and 
differences between the recently published 
Fawkner-Corbett et al., (Cell, 2021) study in 
Table R1 at the end of this document. In 
addition, we perform logistic regression 
analysis to directly compare the developing 
ENS cells between two studies. 
 
Overall, we observe a good correspondence 
between cells in the present study and those 
described in Fawkner-Corbett et al., (Cell, 
2021) (Figure R25). In the present study we 
annotate cells based on mouse dataset 
(Memic et al., Gastroenterology 2018) and 
describe the branching events occurring at 
different developmental stages. 
 
In short, Glia 1 (DHH+) cells matched with 
“Lymphoid associated glia”, Glia 2 (ELN+) 
matched with intraganglionic glia and Glia 3 
(BCAN+) with Submucosal glia (Figure R25). 
The cell names in (Fawkner-Corbett et al., 
Cell 2021) were assigned based on gene 
expression and validation for the location of 
these subtypes was not provided, hence we 
decided to keep the Glia1-3 nomenclature. 
 
Branch B cells matched with 
Neuroendocrine (1), while Branch A IPAN/IN 
with Interneurons and Neuroendocrine (2) 
subsets described in this study (Figure R25). 
 
Branch A (eMN) matched with interneurons 
that were annotated based on expression of 
TAC1 and PENK. As the reviewer 
suggested, these genes were also indicative 
of ENC1-4 and excitatory motor neurons. 
Based on this and genes shared between 
Branch A and B eMN cells as in Figure R18, 
we decided to keep their annotation and 
  clarify this in text as follows: 
 
“...and a population resembling excitatory 
motor neurons (eMN) marked by expression 
of PENK, TAC1 and SLC18A3 
(Supplementary Fig. 5c-d). Similar 
population was recently described in the 




Figure R25: Heatmap showing percentage 
of cells matching between ENS cells 
described in this study and cells from 
Fawkner-Corbett et al., Cell 2021 dataset 
(Predicted). Timepoints 6-17pcw 
 
These results are included in the 
Supplementary Fig 5e of the revised 
manuscript. 
3.13 g) Hirschsprung disease risk genes in 
dataset: Risk genes for HSCR are 
extensively investigated and have 
resulted in the identification of many 
genes that can explain the aganglionic 
phenotype (replicated in murine models). 
RET, GDNF, NRTN, SOX10, EDNRB, 
EDN3, ECE1, ZFHX1B, PHOX2B, 
KIAA1279, TCF4 are major HSCR risk 
genes. Studies have also linked 
SEMA3A, MAPK10, NRG1, SOX2, 
BACE2 and GFRA1 (Tang et al., 
Gastroenterology 2018). Note that genes 
involved in ENS development have been 
investigated as candidates in many 
We agree with the reviewer’s comment and 
as recommended, we limit the analysis to 
the major risk genes suggested by the 
reviewer (RET, GDNF, NRTN, SOX10, 
EDNRB, EDN3, ECE1, ZEB2 (ZFHX1B), 
PHOX2B, KIF1BP (KIAA1279), TCF4) as 
well as those published in Tang et al., 
Gastroenterology 2018. 
 
As suggested by the reviewer, we have 
amended the text and updated the Figure 3 
to show the expression of HSCR-disease 
genes across neural subsets (Figure R26a). 
 
Reassuringly, we did not observe the 
studies, where some have been linked 
(HOXB5) - while others have been 
disproven to contribute to HSCR, 
including ASCL1 (Carter et al., 2012 J 
Hum Genet.) Please limit your annotation 
to confirmed HSCR-disease linked genes 
expression of GDNF, NRTN or EDN3 in the 
neuronal lineages. Instead these genes 
were expressed by stromal and smooth 
muscle cells (Supplementary 5j and Figure 
R26b). 
and do not include own candidate genes 
(remove ASCL1, TLX2 and possibly 
others). Carefully review your HSCR risk 
genes. The illustration in major Figure 4G 
is questionable as it fails to illustrate the 
fine validation provided by this paper of 
already 
suspected transcription factors, cell- 
interactions and receptor/ligand 
interactions and instead high-lights new 
interactions that are not substantialized 
by experiments nor warranted from 
unexplained phenotypes in HSCR. 
Instead, for the HSCR field to gain the 
most from your resource , please make a 























  ENCC/glia Enteric neurons  
significant HSCR risk genes. This could    
identify new leads to be followed up by 
experiments. It is for example very 
interesting that Ret is higher expressed in 
the colon than in the small intestine. Note 
that ERBB2 and NRG1 variants are only 
found in very few HSCR patients and that 
there are other sources of NRG1, 
including sub-epithelial mesenchyme 
(Holloway et al., Cell Stem Cell In Press) 
and smooth muscle cells and fibroblasts 
(Elmentaite et al., Developmental Cell 
2020). It is also fine to include genes 
previously implicated in ENS 
development either in the same or 
separate table, but they could be denoted 
“critical for ENS 
development” or something similar. 
 
It is however true that patients do 
experience life-long complications 
including enterocolitis (Gosain et al 2016 
Pedatr Surg Int) and an increased risk to 
develop Crohn’s disease (Granström et 
al., 2017 JPGN). Hence, there are 
Figure R26: a) Heatmap with mean 
expression of Hirschsprung’s- disease 
associated genes across developing neural 
subsets separated by region of origin (small- 
pink vs large- blue intestine) and 
developmental time point (6-11pcw- purple 
and 12-17pcw- yellow). b) Dotplot with key 
Hirschsprung’s disease-associated ligand- 
receptor genes in the whole fetal dataset. 
Dashed arrows indicate ligand-receptor 
relationship. 
 
We discuss these findings in the revised 
manuscript as follows: 
 
“To identify neural cells involved in 
Hirschsprung’s disease, we screened for 
expression of known Hirschsprung’s 
disease-associated genes 19,20. To control for 
variability in the bowel region in which 
patients experience Hirschsprung's disease, 














 aspects about HSCR that we still do not  
understand that possibly extends beyond The   majority   of   Hirschsprung’s   disease- 
ENS differentiation and colonization. associated  genes  were  expressed   across 
However, the “new” cell-cell interactions multiple differentiating populations with 
indicated by receptor-ligand matching do varying  intensity  (Figure  3e).  For example, 
not seem to reach these gaps in TCF4   and   ZEB2   was   expressed across 
knowledge, are highly speculative, not neural subsets, while MAPK10, PHOX2B and 
backed up with functional evidence or RET  were  highly  expressed  by    neuronal 
HSCR tissue stainings. Your conclusions branches  and  SOX10,  SOX2  and  BACE2 
that the analysis implicate fetal branch 2b enriched in the glial compartment (Figure 3d). 
and ICC/SCM interactions in Expression  levels  of  disease  genes    also 
pathogenesis of Hirschsprung disease varied between  neuron  Branches A  and B. 
(results) and that your high resolution For  example,  RET  was highly expressed in 
genomic definition uncovers new insights Branch  A,  but  not  in  Branch  B    neurons. 
into both rare and common diseases (in Interestingly, RET was more highly 
the introduction), represents two expressed by colonic neuroblasts and Branch 
statements that are exaggerated. Please A  (iMN)  neurons, while  ZEB2  and EDNRB 
refrain from too much speculation. It is were  more  highly expressed across colonic 
enough to show the gene expression of glia and neuroblast subsets  (Figure 3e).   In 
HSCR genes in your addition, key ligands implicated in 
different cell populations and conclude Hirschsprung’s   disease,   including  GDNF, 
that they are expressed more wide- NRTN and EDN3 were primarily   expressed 
spread than previously appreciated (or in by mesothelium, smooth muscle cells (SMC) 
novel cell populations). Please amend and interstitial cells of Cajal (ICC) 
figures, introduction and results (Supplementary Fig. 5j), as described 
accordingly. previously. 
 
Together, our analysis shows broad 
 expression of Hirschsprung’s disease- 
 associated genes across neural and 
 ICC/SMC   cells,   implicating   these   neural 
 subsets in this disease pathogenesis. “ 
3.14 h) Unnecessary speculation: Page 7 row 
326: Authors identify NTrk3 expression in 
an glial population (denoted pro- 
myelinating schwann cells) and try to link 
this expression to the previous 
observation of reduced IPANs in NTrk3 
or Nt3 mutant mice. However, Ntrk3 is 
We have now removed this section from the 
revised manuscript. Thank you. 
 expressed in IPANs (Morarch et al., 
2021), so a much more straight-forward 
explanation would be the intrinsic 
expression of this receptor. Please 
remove this speculation. 
 
3.15 4) The authors admit that extensive 
single cell sequencing of human gut 
tissue at different stages has collectively 
been carried out in recent time and 
indicate that they intend to provide a 
holistic analysis. As such it would be very 
helpful for the field if the authors could 
put their new atlas into perspective of 
recently published studies. For instance, 
how does the human gut RNA-seq 
dataset and analysis of Han et al., 2020 
Nature; May-Zhang et al., 
Gastroenterology 2020; Drokhlyansky et 
al., 2020; Holloway et al., Cell Stem Cell; 
2020; Cao et al., Science 2020 and 
Fawkner-Corbett et al., Cell 2021 
compare to the current manuscript? 
In response to the reviewer’s comment, we 
provide Table R1 summarising the key 
features of the currently available datasets in 
comparison to our study. 
 
The studies published so far focused either 
exclusively on human developmental stages 
(Holloway et al., Cell Stem Cell; 2020; Cao 
et al., Science 2020 and Fawkner-Corbett et 
al., Cell 2021) or disease comparisons from 
a single adult anatomical location (Smillie et 
al., Cell 2019; Martin et al. Cell 2019). 
 
In contrast, here we focus on comparisons 
between fetal and healthy adult intestinal 
cells from multiple locations. A unique 
feature of our study is sampling of fetal as 
well as adult mesenteric lymph nodes 
draining the gut. Finally, we would like to 
emphasise that we hypersample the adult 
intestinal tract in detail across 11 intestinal 
locations and mesenteric lymph nodes, 
which has never been done before. 
 
We summarise the cell types described in 
studies published so far (Table R1) and 
would like to emphasize that the present 
study includes a more detailed annotation of 
fetal immune cells with many cell states 
described for the first time in the gut (e.g. 
presence of CLP, Pro-B cells, ILCPs, 
Megakaryocytes). 
 
In the epithelial compartment, we also 
capture Microfold, enteroendocrine subsets 
and Tuft cells for the first time in human 
development. We also describe 
transcriptomes of BEST4+ cells in the small 
  intestine and BEST2+ Goblet cells in the 
colon- cell types that have not been 
captured thus far. 
 
In the stromal compartment, we uniquely 
identify cells that likely organise lymphoid 
organs, including FDCs and T reticular cells 
and define subsets of lymphatic endothelial 
cells. 
3.16 Minor issues: 
1) At many location, you refer to the ENS 
as “Neuronal” (Figure 1, Supplementary 
Figure 2, Results, Introduction). It is more 
appropriate to use the term “Neural” as 
this encompasses both neuronal and glial 
types/fates. Please change Neuronal to 
Neural when you refer to the whole ENS. 
Thank you for highlighting this 
nomenclature. We have now changed 
“Neuronal” to “Neural” where appropriate. 
3.17 2) Figure 1A. Labelling of sampled areas 
on fetal tissue only states ileum. The 
proximal and mid ileum appears to be 
placed in the fetal duodenum and 
jejunum. Please correct sampling area or 
labelling of area. 
We clarify that “proximal small intestine” 
encompases fetal region that will develop 
into adult duodenum and jejunum. We 
change the labelling of the area in Figure 
1A. 
3.18 3) P52; row 168. 3 is missing in 
NEUROG+ 
Thank you, we have corrected this error. 
3.19 4) Supplementary Figure 1b. The label 
indicates presence of Glia in red, 
however no such cells are discernable in 
the figure 
There is a small population of glial cells at 
the very top and centre of the UMAP of 
Figure 1b. We have added a circle around 
this population for clarity. Thank you. 
3.20 5) Page 6; Row 265: It is questionable to 
refer to terminal glia markers Plp1, 
Sox10, S100b and so as “neural crest 
precursor genes”. Perhaps it is enough to 
define these markers as terminal glial 
markers without referring to neural crest. 
We have redefined these genes as terminal 
glial markers as recommended. Thank you. 
3.21 6) Page 6 Row 242: What do you mean 
by “a shift” in ENS development? Why 
did such shift enable ENCC 
investigation? 
By ‘shift’ in ENS development we are 
referring to the dramatic change in the 
neural cell types present between 10pwc 
and 12 pwc. By capturing ENCCs and this 
diversification of cell types, we had the 
opportunity to study the differentiation of 
  neuronal cells from the ENCC progenitor. 
We have now removed this statement from 
the revised manuscript to avoid confusion. 
3.22 7) Bnc2 is misspelled in results and figure 
legend 4. 
We thank the reviewer for highlighting this 
error that we have now corrected in the 
revised manuscript. 
3.23 8) Abstract: It is enough to say that you 
define glial and neuronal cell populations 
in the developing enteric nervous system 
(no need to say novel – most are already 
defined in the mouse). If you want to use 
novel, only the glial subsets appear truly 
novel and previously not described. 
We have restricted the use of “novel” when 
referring to neural subsets in the revised 
manuscript. 
3.24 9) Page 3; Row135: Reference should be 
Figure 1E,F. 
We have fixed this in text. Thank you. 
3.25 10) Page 5; Row 190: Rephrase “IBD 
pathogenesis is due to”, you probably 
mean “IBD pathology is due to”, or “IBD 
pathogenesis involves impaired 
intestinal….” 
We have fixed this in text. Thank you. 
3.26 11) There are duplicated papers in the 
reference list (for instance Drokhlyansky) 
We have fixed this in text. Thank you. 
3.27 12) It would be helpful with a table 
indicating the number of cells in each 
sample type and the 103 cell types/states 




We provide Supplementary Table 2 with the 
number of cell types/states by biological 
(region, age group, sample name) as well as 
technical (dissociation fraction) factors. 
Referee #4: 
4.1 This very broad-ranging, highly ambitious 
study examines fetal, pediatric and adult 
gut and lymph node tissues at single cell 
resolution, including 11 distinct 
We sincerely thank the reviewer for their 
time in reviewing our manuscript and for 
appreciating its scope and value of its 
insights into gut development. It is our hope 
 intestinal/secondary lymph node 
locations. Strengths of the study include 
its "time and space" analyses, providing 
invaluable single cell insight into gut 
development. The sharing of data and 
code through the Human Cell Atlas and 
will provide an enormously useful 
resource for the community. The time- 
series analyses provide an important re- 
definition of gut development at the 
single cell level. This is effectively 
leveraged for advancing Hirschsprung's 
disease (aganglionic megacolon) 
pathogenesis, a developmental disorder, 
but somewhat less so for inflammatory 
bowel disease (IBD). 
that this manuscript and dataset will be of 
substantial value to the scientific community. 
We have taken onboard the reviewer’s 
helpful suggestions and made changes as 
detailed below. 
4.2 Major 
1. Consistency and developmental 
differences in sampling capture. 
Supplementary Table 1 should include 
cellular yields for each of the samples 
(EPCAM+/CD45-, CD45+EPCAM-) to 
provide insight into the consistency, 
replicability and robustness of findings. 
This is particularly important as many of 
their figures with respect to time-series 
changes may reflect only one sample 
(would be important to clarify). The 
description of the pediatric ileal tissues is 
not described beyond enteroid recovery; 
however, additional pediatric tissue 
results are reported beyond epithelial 
cells. The description of the fetal and 
adult tissue cell isolations implies that 
full-thickness digestion was performed; 
given their sorting strategy, how do the 
authors interpret the marked relative 
mesenchymal enrichment observed in 
fetal tissues, relative to post-natal tissues 
(Figure 1C)? Full-thickness digestion and 
differences between fetal and post-natal 
processing and cell capture efficiencies 
will have marked 
Cell isolation from fetal samples was done 
on the full thickness of the gut, while adult 
samples were large sections of the mucosa 
and pediatric samples were collected as 
biopsies. All samples were enriched using 
magnetic-activated cell sorting (MACS) 
protocol, which leads to less pure 
enrichment than by FACS. Therefore, 
although pediatric samples were enriched 
for EPCAM+ cells, we still capture a large 
proportion of immune cells in these samples. 
 
To rigorously estimate the impact of 
biological factors on cell type composition 
while accounting for the effect of sorting 
strategy as well as other technical factors, 
we modeled the number of cells for each 
sample (n=160 samples in total) and cell 
lineage (9 different cell lineages in total) 
combination using a generalised linear 
mixed model with a Poisson outcome. The 5 
clinical factors (Age group, Donor, Biopsy or 
not, Disease status and Gender) and 4 
technical factors (Enrichment fraction, 10x 
kit version, Liberase enzyme and Sample) 
were fitted as random effects to overcome 
the collinearity among the factors. The effect 
of each clinical/technical factor on cell 
 differences in the interpretation of many 
items in Figure 1. 
lineage composition was estimated by the 
interaction term with the cell lineage. The 
‘glmer’ function in the lme4 package 
implemented on R was used to fit the model. 
The standard error of variance parameter for 
each factor was estimated using the 
numDeriv package. The results of this 
analysis were provided in Supplementary 
Fig. 2c-d as well as Figure R27 below. The 
detailed statistical method is demonstrated 
in Supplementary Note Section 2. 
 
For example, the analysis shows that the 
standard scRNA-seq does not increase nor 
decrease the epithelial cells, while EPCAM+ 
MACS enrichment increases epithelial cells 
by ~5 times (Figure R27a). The 
mesenchymal cells were significantly 
enriched in the 1st and 2nd trimester of 
development compared to postnatal 
samples. Age group and enrichment fraction 






Figure R27: a) Dotplot where the fold 
change represents the enrichment (or 
depletion, low fold change) of cells 
compared with baseline. The local true sign 
rate (LTSR) value represents statistical 
significance of the fold change estimate 
ranging from 0 to 1, where 1 represents a 
confident estimate. b) The forest plot 
showing the relative importance (SD) of 
each technical/biological factor on the cell 
  type proportion. 
4.3 2. Figure 2A-B is a highly interesting 
time-series analyses of relative cell 
fractions, which effectively leverages the 
strength of this study, namely the time- 
series fetal datasets. As classified 
presently, there are marked small vs. 
large intestinal differences prior to the 
"developmental shift" defined in Fig 2B as 
between 10-12 weeks. For example, for 
the large intestine, the "crypt" clusters" 
arise quite abruptly after the "shift" which 
doesn't necessarily make sense, as large 
intestinal crypts include both enterocytes 
and goblet cells. Also, LGR5 and other 
stem cell markers, should anchor the 
crypt development descriptions. Ideally, 
the empiric serial fetal fractions (Fig 2B) 
could empirically justify the time-series 
predictions more explicitly (Fig 2A), 
especially with respect to the secretory 
vs. transit-amplifying/enterocyte 
dichotomy. Missing in the large intestinal 
analysis is a description of the Paneth 
cell equivalents, described by some 
groups as REG4+ cells. 
Finally it is well known that even within 
small or large intestine, marked cellular 
composition differences exist between 
regions (proximal to distal), so in text 
and/or more concise summaries in 
supplementary materials (e.g. UMAPs by 
regions with small or large intestine) 
should be provided. 
We have now substantially revised Figures 
2a-b taking into account the reviewers’ 
comments (please also see point 1.10). We 
have maintained the developmental shift to 
draw attention to the abrupt shift in mature 
epithelial cell types at 10-12pcws particularly 
in the large intestines (also Figure 2c). We 
believe that both the colonic progenitors and 
crypt cells (now redefined as stem cells) 
may give rise to the small number of 
colonocytes and goblet cells detected during 
early development. We have taken the 
reviewer’s advice and refined “crypt” cell 
annotation specifying stem cell (LGR5+) 
versus TA cells. 
 
To provide quantitative evidence for the 
developmental relationship between 
epithelial cell types in Figure 2a, we have 
performed RNA velocity analysis and 
projected these results onto the revised 
UMAP (also shown below as Figure R10). 
This supports the bifurcation of intestinal 
stem cells into secretory and absorptive 
enterocytes/colonocytes in both fetal 
development and adulthood. 
 
 
Figure R12: UMAP of epithelial cell types 
detected in single cell RNAseq dataset of (a) 
fetal small and large intestine and (b) pooled 
pediatric and adult intestinal samples. RNA 
velocity analysis is overlaid on UMAP. 
 
We observe REG4-expressing Goblet and 











  that could represent the Paneth cell 
equivalent mentioned by the reviewer. 
 
 
Figure R28: Dotplot with expression of 
REG4 in pediatric and adult epithelium. 
 
Additionally, we have now provided umap 
plots colored by intestinal region in 


































Figure R29: UMAP of fetal (top) and pooled 
pediatric and adult (bottom) single epithelial 
cells coloured by intestinal region of origin. 
4.4 3. Figure 2E-G: The findings of immune 
receptors, especially for IgG on Tuft cells 
is potentially quite important, but with the 
present datasets, the IBD connection is 
quite speculative; lines 190-198 and 226- 
239 are not particularly informative. 
Rather, I interpreted pre-natal presence 
in the context that IgG uniquely can 
traverse the placenta, thereby providing 
Thank you for the suggestion and please 
also refer to our responses in 1.8 and 3.3 
above. 
 
We agree that the link between IgG sensing 
on tuft cells and IBD is speculative and have 
now moved this in the discussion. We have 
also removed Fig 2d- the comparison 
between Crohn’s and UC. We agree with the 
 
 passive immunization generally and 
potential to activate Tuft cells. Post- 
natally, tuft cells mediate type 2 immunity, 
and Crohn's disease is clearly a type 1 
response; the modest increase in PLCG2 
(Supp Fig 3E) is not a particularly 
compelling/strong tie-in to IBD 
pathogenesis. I could not understand 
what points were trying to being made in 
Fig 2D with the Crohn's disease vs. 
ulcerative colitis comparison, and 
deleting these sections should be 
strongly considered, especially as this 
general tie-in is alluded to in their 
Developmental Cell 2020 manuscript. 
reviewers interpretation that FCGR2A 
expression by a subset of tuft cells may 
facilitate tuft cell activation via IgG traversing 
the placenta during late stages of in utero 
development (2nd/3rd trimester), particularly 
since tuft cells are only detectable in our 
data from second trimester and we see little 
evidence of fetal B cell activation. During 
infancy, IgG in maternal milk may similarly 
provide passive protection. We have added 
this discussion to the revised manuscript: 
 
“In the context of fetal development, IgG can 
uniquely traverse the placenta and provide a 
potential route for tuft cell activation in utero. 
Additionally, IgG in maternal breast milk may 
activate tuft cells and provide passive 
immunity more generally during infancy. Two 
missense variants of PLCG2 have been 
linked to aberrant B cell responses in early 
onset IBD 14,15 and primary immune 
deficiency 16. It is possible that tuft cells, via 
PLCG2 signalling, could also contribute to 
IBD pathology and immune-related disease, 
a link that requires further investigation.” 
4.5 4. The application of their datasets to 
Hirschrung's disease genes (e.g. Ret, 
EDNRB) provides a fascinating glimpse 
into disease pathophysiology with 
interesting validation by RNAscope (Fig 
3D) at 15 PCW (the failure of ganglion 
cell migration is believed to be prior to 
this timepoint). However missing in 
Figure 3 is a time and space summary of 
this migration defect (proximal to distal). 
At the earlier fetal timepoints, can 
RNAscope be applied to track proximal- 
to-distal migration of ganglion cells? 
From a translational perspective, short 
segment (vs. extensive) Hirschsprung's 
only affects the distal rectum, so it would 
be interesting to track a bit more 
precisely the timing of colonic 
innervation. 
Please also see our response to point 
3.13. 
 
Using multiple smFISH, we consistently 
visualise ENCC progenitors (or ganglion 
cells) in the submucosal layer of the 
developing small intestine at 6.5pcw (Figure 
R30). These observations are in line with 
previous reports that ENS colonisation in 
humans starts prior to 4pcw and is complete 
by 7pcw 21. 
We would like to note that early human fetal 
tissue is extremely rare and the access to 
tissue further depends on donor consent. 
Future studies that use model organisms 
may be able to trace ENS development in 
more detail 22,23. 










Figure R30: smFISH images of SOX10+ 
ERBB3+ MPZ+ PLP1+ ENCCs in 
developing human small and large intestine 
at 6.5 pcw. 
 
To address the reviewer’s comment, we 
have included smFISH imaging and a more 
comprehensive summary of proximal-to- 
distal space of ENS development in the 
revised manuscript (Figure 3 and 
Supplementary 5). 
 
Firstly, we separate the cell from 6-11pcw 
and 12-17pcw to inspect the changes in 
differentiation trajectories during early and 
late fetal development (Figure R14a-b). 
 
While at 6-11pcw, ENCCs differentiate 
primarily to neurons via neuroblasts, giving 
rise to two distinct branches- Branch A 
(ETV1+) and Branch B (BNC2+) (Figure 
R14a). This dynamic changes at 12-17pcw 
and becomes biased towards glial 
differentiation (Figure R14b). 
 
To capture proximal to distal differentiation, 
we separate the cell type composition by 
region (Figure R14c). In addition, when 
tracking Hirschsprung's disease-associated 
gene expression, we calculate mean gene 
expression for small and large intestine cell 
subtypes separately and observe higher 
expression of ZEB2 and ENDRB in subsets 
of colonic cells, compared to small intestinal 
cells (Figure R26a). In addition, we observe 
Hirschsprung's disease-associated ligands 
GDNF, NRTN and EDN3 expressed by 
 
PENK,TAC1 
stromal and smooth muscle cells 
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Figure R14: UMAP projection of enteric 
neural crest cell progenitors (ENCC) and 
their progeny at a) 6-11 pcw and b) 12- 
17pcw timepoints. The overlaid arrows show 





































  Selected marker genes are listed for each 
population. c) Barplot with relative 
abundance (percentage %) of cell types 
amongst ENCC-lineage populations as 
described in a) and b) across intestinal 
regions and developmental timepoints. 
 


























Figure R26: a) Heatmap with mean 
expression of Hirchsprung’s- disease 
associated genes across developing neural 
subsets separated by region of origin (small- 
pink vs large- blue intestine) and 
developmental time point (6-11pcw- purple 
and 12-17pcw- yellow). b) Dotplot with key 
Hirschsprung’s disease-associated ligand- 
receptor genes in the whole fetal dataset. 
 
We now summarise these results in the 
revised manuscript in the section entitled 
“Enteric nervous system differentiation 
during development”. 
4.6 5. Figure 4. The focus on ILC populations 
is merited, especially given the 
connection to IBD GWAS genes in Figure 
5G. However, no mention is made of 
ILC2 or ILC1 cells (Yudanin Immunity 
2019). Were they not observed? There is 
a literature that ILC1 cells can derive 
Fetal ILC2 (total 47 cells) initially did not 
generate a distinct Leiden cluster, but we 
distinguish these cells based on high 
expression of HPGDS and PTGDR2 (Figure 
R31 a). We did not detect productive αbTCR 
in the ILC2 subset using VDJ information, 





 from ILC3 cells over time, and certainly in 
IBD. Figure 4E is a lovely juxtaposition of 
CXCL13 (from follicular dendritic cells?), 
CXCR5 and RORC (LTi-like ILC3). 
Would be highly informative to provide a 
corresponding RNAScope co- 
segregation analysis for the LTi-like NK/T 
cells, especially given the anti- 
inflammatory nature of IL17A in Crohn's 
disease. Along these lines, it would be 
illuminating to also provide gene 
expression values for IL22 (epithelial 
protective) and IFNG (multiple cellular 
sources). 
R31 b). As expected IL13 and IL22 were 
expressed by ILC2 and adult ILC3, 
respectively. We now include ILC2 
annotation in main Figure 4 and 
Supplementary Fig. 6. 
 
We could not confidently call ILC1 cells in 
our data as canonical markers for these 
(TBX21, IFNG, CXCR3, IKZF3) were 
expressed broadly by EOMES+ NK cells 
(also group 1 ILCs)(Figure R31 a). This has 
also been observed by other groups 24. 
Mouse studies suggest that fetal gut and 
fetal mesentery harbor ILC2 and ILC3 cells, 
but few ILC1 or NK cells 25. In addition, low 
frequencies of ILC1 and ILC2 have been 
observed in human non-inflamed colon 26,27. 
ILC1 cells are either too rare to be detected 
or cannot be distinguished from NK cells at 
transcriptional level in our data. 
 
We further note that after inspection of G D 
chain expression in our full length smart- 
seq2 data, there are no TCRαb or TCRγδ 
chains in the cells previously named “LTi-like 
NK/T” (Figure R11b). Based on RORC and 
KIT expression and similarity of these cells 
to the adult Th17 subset, we have decided 
to revise their annotation to “NCR- ILC3”. 
Also please see point 1.9 and Figure R11. 
These changes are now included in the main 
Figures 4. 
 





































Figure R11: a) UMAP visualization of T and 
innate-like cells in fetal, pediatric and adult 
samples. Dotted line denotes lymphoid 
tissue inducer (LTi)-like cell types. “ILC3” 
refers to the adult subset. b) Barplot showing 
TRACER analysis of TCR chains in cells 
captured using full-length Smart-seq2 single 
cell sequencing. c) Heatmap showing mean 
probability of cell types matching between 
fetal and Crohn’s disease stromal and 
immune cell populations. 
 
 
We further use smFISH imaging to visualise 
IL17A+ LTi-like NCR- ILC3 cells in tissue 
(Figure R31 c). These cells were rare in 
tissue sections, but were observed near 
other RORC- expressing cells (Figure R31 
c). As the reviewer suggests, CXCL13 is the 
key molecule expressed by mature follicular 
dendritic cells. In addition to CXCL13, mLTo 
cells also express CCL21 and CCL19 that in 
adults are produced by T reticular cells. 
mLTo cells therefore may represent a 
population of fibroblasts with the ability to 
recruit both B and T cells. 


































































  express CXCR5, but instead showed 
expression of other recruitment receptors 
including CCR9 and CXCR6 (Figure R29 d). 
CXCL16, the ligand for CXCR6, was also 
expressed by mLTo as well as myeloid cells, 
while CCL25 (ligand for CCR9) was 
expressed primarily by epithelium. 
Therefore, it is possible that LTi-like NCR- 
ILC3 cells are recruited to the tissue 
independently from mLTo cells. 
 
In addition, to resolve spatial distribution of 
mLTo and ILC3 subsets in the developing 
human gut, we have generated and 
analysed 10x Visium spatial transcriptomics 
data on developing small intestinal regions 
from 13 and 17pcw gut. We use the 
Cell2Location algorithm 17 to map the single- 
cell transcriptomes to the tissue zones 
(Methods). In two tissue sections we 
observe a zone marked by CCL21, CCL19 
and CXCL13 expression (Figure R31 e). As 
expected mLTo cells confidently mapped to 
this tissue zone. In addition, we observe 
mapping of LTi-like NCR+ ILC3 cells to the 
same tissue zone (Figure R31 f). However, 
LTi-like NCR- ILC3 were mapped with less 
confidence possibly due to their low 
abundance. 
 
We now include these results in the revised 
manuscript (Figure 5d and Supplementary 
Fig. 9a-c) and in the section titled “Stromal 







Figure R31: a) Dotplot with expression of 
selected genes in ILC and NK subsets 
identified in this study. b) Number of 
productive TCRαβ chains detected in fetal 
T/ILC cell subsets. c) Multiplex smFISH of 
ILCP (SCN1B+), LTi-like NK/T (IL17A+) and 
LTi-like ILC3 (NCR2+) cells in the human 
fetal intestine (15PCW). d) Dotplot with 
expression of selected recruitment 
molecules in fetal dataset. e) mRNA counts 
of genes expressed in mLTo cells in spatial  
coordinates (CCL21, CCL19 and CXCL13, 




















ILC3 subsets as estimated by cell2Location 
method (bottom panel) across tissue 
sections from 17 pcw ileum (top row) and 13  
pcw ileum (bottom row). White boxes 
highlight developing SLO tissue zones. 
 
4.7 6. Fig 5. While it is logical to conclude the 
manuscript with gut to MLN connections, 
as presently formulated, compelling, 
novel and crisp conclusions are not 
provided. Regarding Fig 5G, not sure 











    
   We have now revised the manuscript to    
sharpen the conclusions of this section as  
follows: 
 
“Our integrated analysis of cell lineages has 
highlighted equivalent cell types and cellular 
enrichment for Crohn's disease as 
opposed to ulcerative colitis, where the 
roles/impact for leukocyte trafficking is 
stronger for the latter. While Figure 5G 
clearly shows substantial overlap in 
effects between different cell types (likely 
all cells contribute to some extent) the 
text concludes by emphasizing ILC3 cells 
(again logical), at the expense of Treg 
cells, with the latter having the highest 
enrichment. The role for differential 
expression in single cell datasets as a 
means of implicating cell subsets is 
logical, but added rigor would be attained 
by applying a complementary datasets 
(Encode, transcriptionally active regions, 
e.g Farh et al., Nature 2015). The Farh et 
al., manuscript implicates Th17 cells and 
not B/plasma cells particularly. 
Given the sparse transcriptome, it is quite 
possible that single cell approaches lack 
the sensitivity to identify key disease 
causing genetic variation. 
networking in mLN and GALT formation 
during second trimester fetal development. 
Furthermore, the presence of the same cell 
signatures in pediatric CD suggests a 
reactivation of these programs for lymphoid 
tissue formation and inflammatory cell 
recruitment during intestinal disease.” 
 
In our additional analysis in the revised 
manuscript, we recapitulate results found by 
Farh et al. (2015). Specifically, we show 
enrichment of Crohn’s-associated GWAS 
genes by Th17, Th1, and ILC subtypes 
(Figure R32a). 
 
The advantage of our study is that 
scRNAseq allows us to resolve rarer and 
less well defined cell subsets. Here, we point 
specifically to the implication of ILC3 cells 
(not described in Farh et al.) because their 
enrichment of the GWAS genes implicates 
the  involvement in lymphoid tissue 
formation in IBD and links to our model of 
recapitulation of fetal programs in SLO 
formation. We now explain this more clearly 
















Figure R32: Top cell types across fetal, 
pediatric healthy and Crohn’s disease, and 
adult data enriched in genes associated with 
a) Crohn’s disease or b) Ulcerative Colitis . 
Cell types with FDR >10% are colored in 
red. 
   
4.8 More generally, the discussion should 
include caveats about the lack of 
sensitivity of the scRNASeq approaches. 
Even if scRNASeq co-localizes Best4 
and CFTR, validation of an exclusive co- 
localization by protein staining (Supp Fig 
2F only shows CFTR) is not provided. 
We have now included the following 
statement in the discussion section, in 
response to the reviewer’s comment: 
 
“Future studies using complementary 
approaches, such as protein staining and 
chromatin accessibility studies will shed 
further light on these novel human cell states 
and their tissue architecture.” 
4.9 Figure 2A: did the authors mean to label 
the upper left-hand cluster "EEC" as 
opposed to "ECC"? 
We have corrected it to EEC. Thank you. 
4.10 4 pediatric samples listed in Figure 1A, 
yet multiple subsequent figures allude to 
5 pediatric samples. 
In total, we include 8 healthy and 7 IBD 
pediatric samples. We have now updated 
the Figure 1a to reflect these numbers. 
4.11 Figure 5F. Can labels more informative 
than "Stromal 1", "Stromal 2" be 
provided, without having to refer to 
supplementary materials. 
For consistency in the field, the stromal cells 
were annotated using nomenclature of 
equivalent colonic stromal cells 28. In 
response to the reviewer’s comment, we 
have included a defining gene in the legend 
of the Figure 5a (e.g. Stromal 1 
(ADAMDEC1+)) that consistently marked 
previously published subsets and those 
described in the this study. 
4.12 Supp Figure H: were pediatric samples 
tested here for comparison? 
Supplementary Figure 6h shows the 
proportion of B cell isotypes present in fetal 
and adult samples. Pediatric samples were 
not included in this analysis as these 
samples were processed using 3’ 10x 
Genomics technology, not compatible with 
VDJ capture. 
4.13 The SARS-Cov19 data (ACE2, TRMPSS) 
is quite interesting and important, but 
sensitivities with respect to stem cell 
infections in utero should be considered. 
We thank the reviewer for highlighting this 
very important consideration. We have now 
changed our description of the data to read: 
 
“This highlights for the first time the 
expression of these viral entry molecules in 
the gut at early life.” 
 
We have also removed speculation that the 
  gut epithelium could be a route for in utero 
infection from the discussion. 
4.14 Line 180: Given the absence of third 
trimester data, it is a bit misleading to say 
that Paneth cells appear post-natally. 
After inspecting the fetal data for the 
expression of defensin (DEFA5 and DEFA6) 
characteristic to paneth cells (Figure R33), 
we find a small population of cells (122 cells) 
that were clustered with differentiating 
Goblet cells. We have now included these 
cells in the fetal data annotation in main 
Figure 2a. These results are in keeping with 
recent publications where similar paneth 
cells were captured in human embryos 18. 
These cells may represent immature paneth 
cells that have been reported to appear at 
around 20-28 post-conception weeks, while 
mature paneth cells are detectable 30 post- 





Figure R33: Dotplot showing expression of 
paneth cell marker genes in the fetal 
epithelial subpopulations. 
4.15 Line 257: DLL3 (vs. DDL3) typographical 
error? 
We have corrected it to DLL3. Thank you. 
4.16 Lines 578-9. The enteric nervous system 
has substantial effects beyond 
peristalsis. 
We agree with the reviewer’s comment. We 
have now removed this statement from the 
revised manuscript. 
 
Table R1: Summary of scRNAseq studies on human and mouse gut. 
Study Region Age Technology Cell type summary 
Han et al., 
2020 
Nature 








Single Cell 5′ 
Library 
Definitive endoderm (further 11 
major clusters with 26 stage- 
specific sub-clusters), 
Splanchnic mesoderm (further 
13 major clusters with 36 stage- 
specific sub-clusters), cardiac, 
other mesoderm (somatic and 
paraxial), endothelium, blood, 
ectoderm, neural, and 
extraembryonic clusters 
May-Zhang Mouse Mice at 6 to Single nuclei Find 13 populations of neuronal 
et al., myenteric 7.5 weeks processed by cells as previously described in 
Gastroenter neurons. and at two 10x Genomics mice and additional 2 main 
ology 2020  separate 3’ Chromium clusters. 
 Validation in times in day. Single Cell  
 human  library and Further subclustering suggesting 
 myenteric Validation on modified 22 distinct populations. 
 ganglia and organ donors version of Cel- 1 glial population filtered out. 
 adjacent 18–35 years. Seq.  
 smooth muscle    
 from  Validation by  
 duodenum,  HCR FISH and  
 ileum and  bulk RNA seq  
 colon.  in humans.  
Drokhlyans Colon cancer Patients were RAISINseq Mouse: 21 neuronal and 3 glia 
ky et al., and normal 35-90 years (labelled clusters. 
2020; colon proximal and of both transgenic  
 to the cancer of genders. mice) with 10x Human: 14 neuronal subsets: 4 
 patients.  Genomics 3’ PEMN, 5 PIMN, 2 PIN, 1 PSN, 
  Mice were Chromium and 2 PSVN subsets 
 Small intestine between 11- Single Cell and  
 and colon of 14 weeks or Smartseq2.  
 mice. 50-52 weeks   
  old and MIRACL  
  included both (mining rare  
  genders. cells)-seq  
   (human and  
   mouse  
   neurons) with  
   10x Genomics  
   3’ Chromium 
Single Cell. 
 
Holloway et Human fetal Fetal 10x Genomics Fetal tissues: epithelium, 
al., Cell tissue at 13.5– development: Chromium Next mesenchyme, EC (7), immune, 
Stem Cell; 19 weeks liver, intestine GEM Single neuronal. 
2020 gestation. and kidney. Cell 3’ Library  
   v2 (lung and HIO: Mesenchyme (4 clusters), 
 HPCS-derived HIO: Day 0 intestine epithelium (9), endothelium (1), 
 organoids (spheroid samples) or V3 neuronal (2). 
 following formation), 3, (kidney  
 hindgut 7 and 14. samples).  
 patterning and    
 specification    
 into a CDX2+    
 intestinal    
 lineage.    
Cao et al., 15 organs: 72 to 129 Three-level 77 main cell types across 
Science Adrenal gland, days post- single-cell tissues. 
2020 cerebellum, conception combinatorial  
 cerebrum, eye,  indexing for Intestine: stromal, SM, Vas. EC, 
 heart, intestine,  gene Lym. EC, Myeloid, Lymphoid, 
 kidney, liver,  expression (sci- epithelial, mesothelial, 
 lung, muscle,  ATAC-seq3). chromaffin, erythroblasts, ENS 
 pancreas,   neurons, ENS glia. 
 placenta.    
 Spleen,   Highlights NEUROG+ pancreatic 
 stomach,   islet epsilon progenitors, TPH1+ 
 thymus,   enterochromaffin cells, G, L, K 
 sentinel tissue.   and I cells, ghrelin+ EEC 
    progenitors. Also HSPCs. 
Smillie et 68 colonic 20 – 77 years 10x Genomics  
al., 2019 biopsies.  Chromium 51 epithelial, stromal, and 
   Single Cell 3′ immune cell subsets, including 
 12 healthy, 18  Library (V2 and BEST4+ enterocytes, microfold- 
 UC donors  V3) like cells, and IL13RA2+IL11+ 
    inflammatory fibroblasts 
Martin et Inflamed and 3 - 40 years 10x Genomics  
al., 2019 uninflamed  Chromium 47 clusters:  stromal (fibroblasts, 
 ileums, and  Single Cell 3′ glial and endothelial cells) and 
 venous blood  Library (V2) seven distinct immune cell 
 from Crohn’s   lineages consisting of T cells, 
 disease   innate lymphoid cells (ILCs), B 






  mononuclear phagocytes 
(MNPs), plasmacytoid dendritic 
cells (pDCs), and mast cells. 
Elmentaite 















Single Cell 3′ 
Library (V2) 
Immune, erythroblast, 
endothelial, neural crest, smooth 
muscle, mesenchymal, and 
epithelial cell populations 
Fawkner- 77 human 8-19PCW Sample Report 101 fetal cell states. 
Corbett et intestinal  hashing and  
al., Cell samples that  10x Genomics 9 intestinal compartments, 
2021 were collected  Chromium annotated by transcriptional 
 from 17  Single Cell 3′ signatures—epithelial, fibroblast, 
 individual  Library (V3). endothelial (EC), pericytes, 
 embryos.  Sample neural (ENS), muscularis, 
   hashing mesothelium, myofibroblast, and 
 Tissues:   immune 
 Terminal ileum,    
 hindgut,    
 Proximal colon,    
 Distal colon    
Present Fetal: Proximal, Fetal (7- 10x Genomics Unique cell transcriptomes 
study middle, 17PCW) Chromium described in this study: 
 terminal ileum,  Single Cell 3’  
 colon, Adult (27-64 (V2) and 5’ (V2) Epithelial compartment: 
 mesenteric years)  - Fetal Tuft cells. 
 lymph node   - Fetal Microfold cells. 
    - small intestinal BEST4+ cells. 
 Adult:   - colonic BEST2+ Goblet cells. 
 Duodenum,   - in vivo NEUROG3+ 
 Jejunum,   progenitors. 
 Ileum,   - NPW+ enterochromaffin cells. 
 Appendix    
 Caecum,   Neuronal: 
 ascending   Comparable clusters observed in 
 colon,   Fawkner-Corbett et al., Cell 
 transverse   2021. However, the annotations 
 colon,   are improved and are now based 
 descending   on the mouse data 30. 
 colon, sigmoid    
 colon, rectum,   Immune: 
mesenteric - ILCP 
lymph node - LTi-like NCR- ILC3 cells 
 - fetal ILC2 
 - adult CX3CR1+ CD8 T 
 - adult Tfh cells 
 - adult MAIT cells 
 - adult and fetal gd T cell 
 subsets (e.g. fetal 
 TRDV2+TRGV9+ gd T cells) 
 - CLP (common lymphoid 
 progenitor) 
 - Distinction of Pro-B cells and 
 Immature B cells 
 - Germinal centre B cells (light 
 and dark zone) and FCRL4+ 
 Memory B cells in the gut 
 (observed in human tonsils 31) . 
 
Myeloid: 





 - FDCs 
 - T reticular cells 
 - lymphatic endothelial subtypes 
 (LEC1-6). 
 - Stromal 1 (CCL11+) in adults. 
 - mLN stromal cells (FMO2+). 
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Reviewer Reports on the First Revision: 
 
Referee #1 (Remarks to the Author): 
The authors have carefully addressed all my previous concerns and strengthened their highly 
valuable resource, which is now ready for publication. 
 
Referee #3 (Remarks to the Author): 
The authors have responded satisfactory to most concerns. However some issues still remain as 
summarized below. Overall I commend the authors for their extensive efforts in assembling, 




The authors have been responsive and presented their data with more sound interpretation. -It 
could be wise to revise the result section slightly to improve clarity. For instance, the detection of 
plcg2 downstream mediators are only mentioned “matter of factly” and not exemplified with gene 
names in the text or with reference to picture (Page 4 175-177). 
-In figure legend, please amend to: i) “Summary schematic of proposed signaling pathways in tuft 
cells”. No experiments have verified any of the suggested interactions in tuft-cells yet. 
-For the experiment showing increased tuft cells, Fcgr2a and Plcg2 in differentiated human organoid 
line, please show the individual data-points in the bar plot and indicate how many 
replicates/experiments (n) were included in the calculation. 
 
Comment 5 (ENS) 
The separation of the datasets into two ranges of stages have led to clearer trajectories/clusters. 
The nomenclature into Branch A and B according to previous murine characterization is good for the 
future clarity in the ENS field. Some other neuron class nomenclature appear to have been solved 
nicely. Thank you for the extensive gene expression on UMAPs for validation of your 
reasoning/claims. 
I would only like to make a few changes: 
 
Comment 8/9 
a) Branch A –two different clusters are specified (denoted IPAN/IN and eMN). Both these clusters 
are defined as ENC12 neurons in the murine dataset (number of cells was too few to subcluster). As 
in mouse, both your cell groups express Ntng1. It was demonstrated in Morarach et al., 2021 (Fig. 
4o) that no Ntng1 fibers are innervating the muscle - hence none of these clusters are likely 
excitatory motor neurons. If this is the case in human remains to be explored, but there is also no 
evidence to classify this group as excitatory MN. These genes are for example expressed in many 
types of interneurons in the CNS where they modify excitation of other neurons. In the mouse both 
these enteric neuron groups express Piezo2 (partly) and could thus be IPANs/INs. The equivalent 
neuron types in the Drokhylansky atlas are PIN3 and PSN3 - as you can see they form a similar 
UMAP pattern as in juvenile mouse ENS. Please amend this nomenclature to IPAN/IN for both 
Branch A “tip-clusters” if you want to assign function to these neurons. Perhaps you could use some 
numbering system to distinguish the clusters within the branches (for instance: Branch A1 (iMN), 
Branch A2 (IPAN/IN), Branch A3 (IPAN/IN)). Please also amend the result text, supplementary 
figures and tables accordingly. Finally – the high-lighted genes for these tip clusters do not 
correspond with the dotplots/differentially expressed gene lists (for instance Grp is stronger in 
IPAN/IN – see also R2:3 below). 
 
b) The most typical markers in mouse for excitatory motor neurons are Calretinin (in 
juvenile/adults), and Enkephalin (Penk), but its known that both enkephalin and Calretinin are 
expressed in subsets, not all eMN and may not be exclusively expressed in eMN (Reiche et al., 1998 
Dtsch Tierarztl Wochenschr 105; and Qu et al., 2008 Cell and Tissue Research). The recent human 
ENS atlas also suggest that there are Penk/Tac high (e.g. PEMN2) and low (e.g. PEMN3) excitatory 
motoneurons. Hence, not only the strong Penk+ neurons are to be considered as excitatory motor 
neurons. Morarach et al suggest that Ndufa4l2 is an early marker of excitatory motor neurons 
(although not expressed in all cells) which stays on in the adult ENS mainly in ENC1-2,4. Bnc2 is 
also indicative of excitatory MN (although some IN also express Bnc2 in the adult). The 
Drokhylansky human atlas also indicate Bnc2 as an excitatory MN marker. I would suggest that both 
Branch B clusters at pcw 6-11 are denoted excitatory motor neurons (they likely correspond most 
closely to ENC1-3). They could be called BranchB1 (eMN), Branch B2 (eMN). It is also clear that a 
subset of your Branch B is immature still, so it is understandably hard to fit them into a neuron 
class. Studies in the mouse (Morarach et al., 2021) suggest that there is significant differentiation at 
the postmitotic stage, even leading to phenotypic switches - hence when considering newly born 
neurons - the final identity is not trivial to acertain. Especially at the older stages, some of newly 
born neurons might be developing submucosal neurons that have not started to express their 
unique markers yet. But it is fine to leave this information out from the manuscript. Adjust the 
nomenclature in all relevant documents including the supplementary figures and tables. Remove or 
adjust markings of excitatory marker genes in Supplementary Fig5 (perhaps this is not necessary 
information, especially as functional studies in human to link these markers to functional groups are 
still lacking). 
 
c) With regards to enriched genes indicated as Branch specific: Is Ramp1 a very selective marker 
for the whole Branch B, and how wide-spread is Kcnj5 in Branch A? Bnc2 and Etv1 appear selective 
and robust for almost the whole branches (although Bnc2 is downregulated in Branch B IPAN, as in 
mouse). If you want to compare to murine ENS, Kcnj5 is not Branch-specific in this organism. See 
above for alternative markers to be considered if they indeed are enriched sufficiently. Ramp1 
appears however rather specific to the beginning of Branch B and could be kept as a marker for this 
cluster (which I suggest you rename eMN or immature eMN as discussed above). 
 
d) Branch A at 12-17 pcw contains the Neurod6+ population, a suggested interneuron. Think about 
the nomenclature in relation to above, whether some numbering would make things clearer (for 
example denoting these Branch A4 (IN)). 
 
e) At 12-17pcw you do not indicate any Branch A IPAN/IN or eMN. Those cells could be too few and 
was outnumbered by the increasing glia and MN populations. Should this be mentioned somewhere 
(perhaps in figure legend in the lack of space in main text)? It is otherwise a bit confusing to the 
reader what happens with these neuron types at older ages. 
 
Comment 11) Regarding glia/progenitors, it looks much cleaner with the separation of datasets into 
two ranges and easier to interpret. The further validation of the three classes of glia in tissue is 
greatly appreciated. 
 
Comment 12) Validation of genes in tissue in previous developing human ENS atlas: the reference is 
not included in the revised manuscript, but you also have removed the discussion on Gdf10, Tgfb 
and so on in the text. Please consider though that this gene expression atlas contains the validated 
immunohistochemical expression of 31 transcription factors and 19 ligand/receptors in the ENS of 
both intestine and stomach at week 5-6 and 7-10, matching your first range of scRNA-seq data-
analysis. Referring to this paper as validating complementing resource could be very valuable for 
the reader. 
 
Comment 13) The presentation and discussion regarding Hirschsprung’s disease genes are also now 
more sound and interesting. Please cite a more general HSCR review or paper for the selection of 
HSCR risk genes in addition to the already selected. For instance Bondurand and Southard-Smith 
2016 Dev. Biol. 
 
Comment 14) Thank you for the up-to-date list of current scRNA-seq datasets of human gut cells. I 
would expect this summary to be extremely useful for the field - consider to include it as an extra 
supplementary Table that you could cite in relation to the sentence at Page 2, row 79-81. The 
extensive description of all datasets as well as the precise list of unique tissues/celltypes/analysis 
only obtained from your study is very valuable for the people in the gut field in guiding them to the 
right data-set for their downstream analysis. 
 
Additional issues in the revised manuscript: 
R2:1) Page 5, Row 193-194. “Premature differentiation of ENCCs leads to Hirschprung’s disease”. 
There are many mechanisms that appear to contribute to the HSCR phenotype, one of them 
premature differentiation, but also aberrant migration, proliferation, survival and neurite outgrowth 
– all together leading up to insufficient cell numbers in the distal colon. While you don’t need to 
explain in detail, please widen the causes to HSCR. 
The rationale to choose the two references are also not clear. One refers to migrational defect 
following an Ernb-mutation, and the other characterize a plausible risk gene for Wardenburg 
syndrome (which have HSCR amongst others). I suggest to cite a recent review for example: 
Bondurand and Southard-Smith 2016 Dev. Biol. 
 
R2:2) The title for Figure 3 could be broader phrased. The detailed description of ENS differentiation 
in human is more interesting and novel than the expression of HSCR risk genes (the genes/cells 
behind the dominant HSCR phenotype aganglionosis is well understood, although gene expression 
shown here could also explain additional subtler defects manifesting at later stages). In addition, 
please define IN: Interneuron 
 
R2:3) It is unclear how the genes were picked to denote the different clusters (Fig 3A-B). In many 
cases the genes are not unique and equally much expressed in other clusters. For instance, Branch 
B is labelled with “Bnc2”, while Branch B (eMN) also express this gene (although it is lower at later 
stages, its not a good distinguishing gene between the two clusters). Likewise, the distinction 
between Branch A (eMN) and Branch A (IPAN/IN) is not portrayed well in the Figure. Both clusters 
show Grp, and eMN even at higher levels, despite this Grp is denoted as an IPAN/IN marker. See 
above also discussion about these two clusters and alternative interpretations. A suggestion are: 
Ntng1/Grp/Tac1/Penk and Ntng1/Grp/Nxph2 as marker genes. As Ntng1 and Etv1 are common 
marker for the two, but are not expressed in the Branch A they would additionally help you separate 
the Branch A Tac1/Penk/Ntng1(Etv1) from Branch B Tac1/Penk/Bnc2 populations. Thus, in the cases 
where a key gene is expressed in several clusters but anyway worth high-lighting it would be better 
to show it in several clusters and instead focusing on the combinatorial gene-code differences. 
These are just examples I detected - please, carefully scrutinize the marker genes indicated in 
Figure/mentioned in the text and pick as selective genes as possible (and/or show combinatorial 
profiles to avoid confusion). 
 
R2:5) Suggested rephrasing: Page 5; 216-217: “While differentiated neuronal cell types were 
abundant at 6-11 PCW, glial cell types were enriched at later stages (12-17 PCW).” 
 
R2:6) Suggested rephrasing Page 6; 246-258: “Our analysis shows broad expression of 
Hirschsprung’s disease-associated genes across neural and ICC/SMC cells, implicating these gut cell 
types in disease pathogenesis.” In addition, this is not a summary of the whole section and could be 
moved up as an ending of the previous paragraph. 
 
R2:7) Does Figure 3e show expression in the myenteric plexus or mesentery? The explanation 
“outside the myenteric plexus” (in figure legend) is a bit unclear. 
 
R2:8) Please correct the citing of Figure 3 in the results section, most are not updated. 
 
R2:9) Carefully check the nomenclature in Figure 3 and make sure the same names are used in a-b 
as f (for example ENCC is not used in the a-b, but in f). Also recheck the supplementary tables for 
the nomenclature used. 
 
R2:10) The difference in Ret expression between small (SI) and large intestine (LI) is with the 
revised clusters less pronounced, and it is doubtful whether it is worth high-lighting. Branch A (IN) 
appears even to have higher expression in SI than LI. The most interesting is probably your first 
sentence, that Ret remains in Branch A, but is downregulated in Branch B, progenitors and glia. The 
comparison between SI and LI with regards to Zeb2 and Ednrb is ok, but rephrase the sentence so 
that it is clear that you compare SI and LI (it was not in the latest revision). Note however that LI is 
always going to lag behind SI in its development due to the rostral-caudal colonization of the gut, 
and general differentiation of the embryo in an rostral to caudal fashion, so the changes might be 
related to this phenomena. Although then Sox10 would also be enriched in LI, which it is not so 
your observed LI-SI differences may be unrelated to the general differentiation. 
 
R2:11) Some mistakes in Figure 3: 
Please go through the gene names to make sure there are no typos. 
-Branch B says Dlx1 at pcw12-17 while it Dlx5 at pcw 6-11. Is this correct or should it be Dlx5 at 
both stages. 
-Neurog6 in Branch A (IN) – should it be Neurod6? 
 
Referee #4 (Remarks to the Author): 
 
The investigators have performed a basic re-analysis of some of the front part of the manuscript, 
added and clarified sample numbers and added new spatial transcriptomics and smFISH data. In 
general, moderate changes to their data visualization have simplified and/or clarified some of their 
major messages, including improved clarity wrt their choices for their ligand receptor mappings. 
They have restricted their  Hirschsprung's associated gene list, and  re-formulated/re-named some 
of their clusters. I agree with the author's statement that tracking fetal time-course with respect to 
proximal to distal migration likely should be held for a more detailed Hirschsprung's focused effort, 
given the difficulty of fetal tissue capture. The relegation of the (often rare subsets) in CD vs. UC is 
appropriate (given the substantial overlap between many clusters), with a space-efficient 
summarizing heat-map kept in Fig 5. This comprehensive and comprehensively referenced gut 
atlas  will represent a "must-review" primer for GI, neurologic and immunologic development and 
disease for advanced level trainees. I have a few remaining questions and concerns. 
 
Major: 
1. Figure 1 overview 
1. 1b can likely be compressed for space. Much of this real estate is not that informative. 
2. In reviewing the fascinating complexity of the enteroendocrine cells, I wonder to what extent the 
very early fetal timepoints might reflect contamination from the pancreatic bud (acknowledged for 
insulin-producing beta, endocrine cells in line 148-9) for exocrine cell subsets as well. In very early 
development, not sure how easy to dissect apart these organs. 
3. 1d. It seems rather unlikely that in the adult samples the fractions of epithelial cells range from < 
2% (duodenum, cecum, rectum) to well over 15% (Sigmoid). I think the general concept that 
transmural vs. biopsy samples results in lower fractions of epithelial cells seems right, however, as 
presented, I feel that this bar-graph is misleading especially for the within adult comparisons. Is it 
possible that differences in sampling capture efficiencies account for this? The doublet removals 
(especially problematic for epithelial cells and given the high fraction of cell removal generally)? 
4. (MInor) 1d. Consider removing the color (or restricting to epithelial green), so as to not confuse 
with 1b/c 
5. 1f. Legend doesn't specify what the red highlights designate. Not sure what the basis for 
transcript inclusion is for this gene list 
 
2. Figure 2. The RNA velocity analyses substantially strengthen the opening to this Figure. Figure 2a 
(fetal) vs. b (ped/adult). I may be mis/over-interpreting the scVelo analyses, but how do the 
authors interpret the M cell differences between pre- vs. post-natal cells? While the post-natal 
analyses appear to make sense (M cells from stem cells), the M cells in fetal appear far from the 
stem cells. This would appear to be in conflict with de Lau et al's findings (PMID 22778137). Does 
this reflect pre- vs. post-natal differences? 
 
3. ILC origins. This may be beyond the scope of this manuscript, given the small number of ILC2 
cells identified, but does appear generally relevant given the tie-in to IBD in Fig 5. Bielecki et al., 
(PMID 33536623) show in skin that tissue resident innate lymphoid cells are sufficient to drive 
inflammation/pathogenicity, implying conversion from ILC2 to ILC3. Do any of the present data 
support this model (small numbers of ILC2 due to transition toward ILC3), or do the authors think 
this merely reflects organ differences between skin and gut? 
 
4. Data Sharing and Supplementary Materials. The authors have provided exhaustive figures and 
tables for the community, which will be incredibly valuable for the community at large. 
Minor 
1. Consistency wrt number of different anatomic sites sampled: 10 (line 51) vs. 11 (line 84). Figure 
1a designates even more locations. Should be consistent or qualify in place the number of sites. 
2. Line 457: change Nerog3+ to Neurog3+ 






















































Author Rebuttals to First Revision: 
 
We thank the editor and reviewers for their time in considering our manuscript. A 
point-by-point response to reviewers’ comments is detailed below. Additional text 
is highlighted in blue and revised changes are highlighted in red. 
 
 Comments Responses 
1.1 Referee #3 (Remarks to the 
Author): 
 
The authors have responded 
satisfactory to most concerns. 
However some issues still 
remain as summarized below. 
Overall I commend the authors 
for their extensive efforts in 
assembling, analyzing and 
presenting this extensive human 
gut cell atlas, which is likely to 
become a valuable resource. 
 
Comment 3) 
The authors have been 
responsive and presented their 
data with more sound 
interpretation. -It could be wise to 
revise the result section slightly 
to improve clarity. For instance, 
the detection of plcg2 
downstream mediators are only 
mentioned “matter of factly” and 
not exemplified with gene names 
in the text or with reference to 
picture (Page 4 175-177). 
-In figure legend, please amend 
to: i) “Summary schematic of 
proposed signaling pathways in 
tuft cells”. No experiments have 
verified any of the suggested 
interactions in tuft-cells yet. 
-For the experiment showing 
increased tuft cells, Fcgr2a and 
Plcg2 in differentiated human 
organoid line, please show the 
individual data-points in the bar 
We thank the reviewer for recognising the 
effort we have made in revising the manuscript 
and for their additional comments. 
 
We have now exemplified the genes involved 
in PLCG2 signaling in tuft cells in text as 
follows: 
 
“... the expression of FCGR2A and 
downstream signalling mediators including 
RAC2, ITPR2, PRKCA and TRPM5 (Figure 2h 
& j) led us to wonder whether tuft cells 
specifically could be responsive to signals from 
immune cells.” 
 
We have changed the legend for Figure 2i as 
suggested by the reviewer. 
 
We also provide individual data-points for the 
human organoid experiments in 
Supplementary Fig. 4 k-l and in Figure R1. The 
experiments were performed in triplicates using 




Figure R1: k-l) Bar plot of relative expression of 
LGR5 and MUC2 (k) and Tuft cell key mRNA 
(l) by intestinal differentiated or undifferentiated 
organoids. 
 plot and indicate how many 
replicates/experiments (n) were 
included in the calculation. 
 
1.2 Comment 5 (ENS) We have renamed the neuronal populations to 
 The separation of the datasets Branch A1 (iMN), Branch A2 (IPAN/IN), Branch 
 into two ranges of stages have A3 (IPAN/IN)) as suggested. 
 led to clearer  
 trajectories/clusters. The We also amended the relevant text, Figures 
 nomenclature into Branch A and (Supplementary Fig. 2, Fig. 5) and Tables. 
 B according to previous murine  
 characterization is good for the For Branch A subsets, we amended the 
 future clarity in the ENS field. highlighted genes in Figure 3a,b as follows: 
 Some other neuron class  
 nomenclature appear to have Branch A1 (iMN)- ETV1/ GAL/ SCGN/ NOS1/ 
 been solved nicely. Thank you SPOCK1 
 for the extensive gene Branch A2 (IPAN/IN)- ETV1/ NTNG1/ GRP/ 
 expression on UMAPs for CHRM3/ NXPH2. 
 validation of your Branch A3 (IPAN/IN)- ETV1/ NTNG1/ GRP/ 
 reasoning/claims. TAC1/ RUNX1/ ONECUT3. 
 I would only like to make a few Branch A4 (IN)- ETV1/ SCGN/ GCGR/ 
 changes: NEUROD6 
 
Comment 8/9 and provide relevant plots in Figure R2 for your 
 a) Branch A –two different convenience: 
 clusters are specified (denoted  
 IPAN/IN and eMN). Both these  
 clusters are defined as ENC12  
 neurons in the murine dataset  
 (number of cells was too few to  
 subcluster). As in mouse, both  
 your cell groups express Ntng1.  
 It was demonstrated in Morarach  
 et al., 2021 (Fig. 4o) that no  
 Ntng1 fibers are innervating the  
 muscle - hence none of these  
 clusters are likely excitatory  
 motor neurons. If this is the case  
 in human remains to be  
 explored, but there is also no  
 evidence to classify this group as  
 excitatory MN. These genes are  
 for example expressed in many 
types of interneurons in the CNS 
where they modify excitation of 
Figure R2: Neural subsets during development 
at a) 6-11pcw and b) 12-17 pcw with revised 
 other neurons. In the mouse both  
 
 these enteric neuron groups 
express Piezo2 (partly) and 
could thus be IPANs/INs. The 
equivalent neuron types in the 
Drokhylansky atlas are PIN3 and 
PSN3 - as you can see they form 
a similar UMAP pattern as in 
juvenile mouse ENS. Please 
amend this nomenclature to 
IPAN/IN for both Branch A “tip- 
clusters” if 
you want to assign function to 
these neurons. Perhaps you 
could use some numbering 
system to distinguish the clusters 
within the branches (for instance: 
Branch A1 (iMN), Branch A2 
(IPAN/IN), Branch A3 (IPAN/IN)). 
Please also amend the result 
text, supplementary figures and 
tables accordingly. Finally – the 
high-lighted genes for these tip 
clusters do not correspond with 
the dotplots/differentially 
expressed gene lists (for 
instance Grp is stronger in 
IPAN/IN – see also R2:3 below). 
highlighted marker genes. c) Dotplot with 
genes highlighted in a-b. 
1.3 b) The most typical markers in 
mouse for excitatory motor 
neurons are Calretinin (in 
juvenile/adults), and Enkephalin 
(Penk), but its known that both 
enkephalin and Calretinin are 
expressed in subsets, not all 
eMN and may not be exclusively 
expressed in eMN (Reiche et al., 
1998 Dtsch Tierarztl 
Wochenschr 105; and Qu et al., 
2008 Cell and Tissue Research). 
The recent human ENS atlas 
also suggest that there are 
Penk/Tac high (e.g. PEMN2) and 
low (e.g. PEMN3) excitatory 
motoneurons. Hence, not only 
the strong Penk+ neurons are to 
be considered as excitatory 
We have amended branch B neuron 
nomenclature as Branch B1 (eMN), Branch B2 
(eMN) and Branch B3 (IPAN), as suggested, 
and adjusted the relevant text, figures and 
tables. We also clarify Branch B1 and B2 
immaturity in text as follows: 
 
“Branch B further differentiated into immature 
excitatory motor neuron (eMN) subsets 
(Branch B1 and B2) that correspond most 
closely to murine ENC1-3 (Figure 3a).” 
 
We also revised genes for Branch B as follows 
and in Figure R2: 
Branch B1 (eMN)- BNC2/ RAMP1/ NXPH4/ 
NDUFA4L2. 
Branch B2 (eMN)- BNC2/ PENK/ HTR7. 
Branch B3 (IPAN)- BNC2/ DLX3/ DGKG. 
 motor neurons. Morarach et al 
suggest that Ndufa4l2 is an early 
marker of excitatory motor 
neurons (although not expressed 
in all cells) which stays on in the 
adult ENS mainly in ENC1-2,4. 
Bnc2 is also indicative of 
excitatory MN (although some IN 
also express Bnc2 in the adult). 
The Drokhylansky human atlas 
also indicate Bnc2 as an 
excitatory MN marker. I would 
suggest that both Branch B 
clusters at pcw 6-11 are denoted 
excitatory motor neurons (they 
likely correspond most closely to 
ENC1-3). They could be called 
BranchB1 (eMN), Branch B2 
(eMN). It is also clear that a 
subset of your Branch B is 
immature still, so it is 
understandably hard to fit them 
into a neuron class. Studies in 
the mouse (Morarach et al., 
2021) suggest that there is 
significant differentiation at the 
postmitotic stage, even leading 
to phenotypic switches - hence 
when considering newly born 
neurons - the final identity is not 
trivial to acertain. Especially at 
the older stages, some of newly 
born neurons might be 
developing submucosal neurons 
that have not started to express 
their unique markers yet. But it is 
fine to leave this information out 
from the manuscript. Adjust the 
nomenclature in all relevant 
documents including the 
supplementary figures and 
tables. Remove or adjust 
markings of excitatory marker 
genes in Supplementary Fig5 
(perhaps this is not necessary 
information, especially as 




















Figure R2: Neural subsets during development 
at a) 6-11pcw and b) 12-17 pcw with revised 
highlighted marker genes. c) Dotplot with 
genes highlighted in a-b. 
 
 link these markers to functional 
groups are still lacking). 
 
1.4 c) With regards to enriched 
genes indicated as Branch 
specific: Is Ramp1 a very 
selective marker for the whole 
Branch B, and how wide-spread 
is Kcnj5 in Branch A? Bnc2 and 
Etv1 appear selective and robust 
for almost the whole branches 
(although Bnc2 is downregulated 
in Branch B IPAN, as in mouse). 
If you want to compare to murine 
ENS, Kcnj5 is not Branch- 
specific in this organism. See 
above for alternative markers to 
be considered if they indeed are 
enriched sufficiently. Ramp1 
appears however rather specific 
to the beginning of Branch B and 
could be kept as a marker for 
this cluster (which I suggest you 
rename eMN or immature eMN 
as discussed above). 
RAMP1 and BNC2 were both similarly 
enriched in Branch B, and RAMP1 was more 
specific to Branch B neurons than BNC2 
(Figure R3). We have decided to highlight 
BNC2 based on their similarity to murine 
Branch B neurons (Monarch et al., 2021) and 
humans 
(Drokhylansky et al., 2020). 
Similarly, we highlighted ETV1 for species 
similarity and KCNJ5 as a more selective 
marker for Branch A neurons (Figure R3). 
However, because the KCNJ5 gene is not 
conserved across species as suggested by the 
reviewer, we do not mention this gene in the 
Figure 3 (Figure R2). 
 
 
Figure R3: Expression of BNC2, RAMP1, 
ETV1 and KCNJ5 in developing neurons 6-11 
and 12-17PCW samples. 


















Figure R2: Neural subsets during development 
at a) 6-11pcw and b) 12-17 pcw with revised 
highlighted marker genes. c) Dotplot with 
genes highlighted in a-b. 
1.5 d) Branch A at 12-17 pcw 
contains the Neurod6+ 
population, a suggested 
interneuron. Think about the 
nomenclature in relation to 
above, whether some numbering 
would make things clearer (for 
example denoting these Branch 
A4 (IN)). 
Thank you for this suggestion, we have 
renamed this population to Branch A4 (IN) in 
the revised manuscript. 
1.6 e) At 12-17pcw you do not 
indicate any Branch A IPAN/IN 
or eMN. Those cells could be too 
few and was outnumbered by the 
increasing glia and MN 
populations. Should this be 
mentioned somewhere (perhaps 
in figure legend in the lack of 
space in main text)? It is 
otherwise a bit confusing to the 
reader what happens with these 
neuron types at older ages. 
Thank you, we address this in the legend of 
revised Figure 3: 
 
“Branch A2 and A3 (IPAN/IN) subsets were not 
observed at 12-17 PCWs, possibly because 
these subsets were outnumbered by the 
increasing glial populations.” 
 
1.7 Comment 11) Regarding 
glia/progenitors, it looks much 
cleaner with the separation of 
datasets into two ranges and 
easier to interpret. The further 
validation of the three classes of 
glia in tissue is greatly 
appreciated. 
We agree with the reviewer, many thanks for 
their useful suggestion. 
1.8 Comment 12) Validation of 
genes in tissue in previous 
developing human ENS atlas: 
the reference is not included in 
the revised manuscript, but you 
also have removed the 
discussion on Gdf10, Tgfb and 
so on in the text. Please consider 
though that this gene expression 
atlas contains the validated 
immunohistochemical expression 
of 31 transcription factors and 19 
ligand/receptors in the ENS of 
both intestine and stomach at 
week 5-6 and 7-10, matching 
your first range of scRNA-seq 
data-analysis. Referring to this 
paper as validating 
complementing resource could 
be very valuable for the reader. 
Thank you, we include this reference in text as 
follows: 
 
“Expression of transcription factors (ETV1) and 
other signalling molecules were previously 
validated in situ in a complementary resource of 
the human gut.23” 
1.9 Comment 13) The presentation 
and discussion regarding 
Hirschsprung’s disease genes 
are also now more sound and 
interesting. Please cite a more 
general HSCR review or paper 
for the selection of HSCR risk 
genes in addition to the already 
selected. For instance 
Bondurand and Southard-Smith 
2016 Dev. Biol. 
Thank you, we include Bondurand and 
Southard-Smith 2016 Dev. Biol. reference as 
follows: 
 
“To identify neural cells involved in 
Hirschsprung’s disease, we screened for 
expression of known Hirschsprung’s disease- 
associated genes (Tang et al. 2018; Zhang et 
al. 2017; Bondurand and Southard-Smith 
2016).” 
1.10 Comment 14) Thank you for the 
up-to-date list of current scRNA- 
seq datasets of human gut cells. 
I would expect this summary to 
Thank you, we have included this table as 
Table 1 and cite it as suggested by the 
reviewer. 
 be extremely useful for the field - 
consider to include it as an extra 
supplementary Table that you 
could cite in relation to the 
sentence at Page 2, row 79-81. 
The extensive description of all 
datasets as well as the precise 
list of unique 
tissues/celltypes/analysis only 
obtained from your study is very 
valuable for the people in the gut 
field in guiding them to the right 
data-set for their downstream 
analysis. 
 
1.11 Additional issues in the revised 
manuscript: 
R2:1) Page 5, Row 193-194. 
“Premature differentiation of 
ENCCs leads to Hirschprung’s 
disease”. There are many 
mechanisms that appear to 
contribute to the HSCR 
phenotype, one of them 
premature differentiation, but 
also aberrant migration, 
proliferation, survival and neurite 
outgrowth – all together leading 
up to insufficient cell numbers in 
the distal colon. While you don’t 
need to explain in detail, please 
widen the causes to HSCR. 
The rationale to choose the two 
references are also not clear. 
One refers to migrational defect 
following an Ernb-mutation, and 
the other characterize a plausible 
risk gene for Wardenburg 
syndrome (which have HSCR 
amongst others). I suggest to 
cite a recent review for example: 
Bondurand and Southard-Smith 
2016 Dev. Biol. 
Thank you, we have included a wider 
description of causes of HSCR in the text, and 
have updated the associated reference: 
 
“Insufficient numbers of ENCCs in the distal 
colon due to numerous differentiation, 
migration, proliferation or survival defects can 
lead to Hirschsprung's disease.” 
 
We have replaced the two cited papers with 
Bondurand and Southard-Smith 2016 Dev. 
Biol. as suggested. 
1.12 R2:2) The title for Figure 3 could 
be broader phrased. The 
detailed description of ENS 
differentiation in human is more 
interesting and novel than the 
expression of HSCR risk genes 
(the genes/cells behind the 
dominant HSCR phenotype 
aganglionosis is well understood, 
although gene expression shown 
here could also explain 
additional subtler defects 
manifesting at later stages). In 
addition, please define IN: 
Interneuron 
Thank you for this suggestion. We re-titled the 
Figure 3 to “Cells of the developing enteric 
nervous system”. 
 
We have also defined IN as an interneuron in 
this figure legend. 
1.13 R2:3) It is unclear how the genes 
were picked to denote the 
different clusters (Fig 3A-B). In 
many cases the genes are not 
unique and equally much 
expressed in other clusters. For 
instance, Branch B is labelled 
with “Bnc2”, while Branch B 
(eMN) also express this gene 
(although it is lower at later 
stages, its not a good 
distinguishing gene between the 
two clusters). Likewise, the 
distinction between Branch A 
(eMN) and Branch A (IPAN/IN) is 
not portrayed well in the Figure. 
Both clusters show Grp, and 
eMN even at higher levels, 
despite this Grp is denoted as an 
IPAN/IN marker. See above also 
discussion about these two 
clusters and alternative 
interpretations. A suggestion are: 
Ntng1/Grp/Tac1/Penk and 
Ntng1/Grp/Nxph2 as marker 
genes. As Ntng1 and Etv1 are 
common marker for the two, but 
are not expressed in the Branch 
A they would additionally help 
you separate the Branch A 
Tac1/Penk/Ntng1(Etv1) from 
We provide an updated list of highlighted 
genes including the genes suggested by the 
reviewer and their expression in the dotplot in 



















Figure R2: Neural subsets during development 
at a) 6-11pcw and b) 12-17 pcw with revised 
highlighted marker genes. c) Dotplot with 
genes highlighted in a-b. 
 
 Branch B Tac1/Penk/Bnc2 
populations. Thus, in the cases 
where a key gene is 
expressed in several clusters but 
anyway worth high-lighting it 
would be better to show it in 
several clusters and instead 
focusing on the combinatorial 
gene-code differences. These 
are just examples I detected - 
please, carefully scrutinize the 
marker genes indicated in 
Figure/mentioned in the text and 
pick as selective genes as 
possible (and/or show 
combinatorial profiles to avoid 
confusion). 
 
1.14 R2:5) Suggested rephrasing: 
Page 5; 216-217: “While 
differentiated neuronal cell types 
were abundant at 6-11 PCW, 
glial cell types were enriched at 
later stages (12-17 PCW).” 
Thank you, we have now re-phrased this 
sentence as suggested by the reviewer. 
1.15 R2:6) Suggested rephrasing 
Page 6; 246-258: “Our analysis 
shows broad expression of 
Hirschsprung’s disease- 
associated genes across neural 
and ICC/SMC cells, implicating 
these gut cell types in disease 
pathogenesis.” In addition, this is 
not a summary of the whole 
section and could be moved up 
as an ending of the previous 
paragraph. 
Thank you we updated this as follows: 
 
“Here we mapped the differentiation of neural 
cells from the precursor cell states, showing 
that neurogenesis preceeds gliogenesis. In 
addition, our analysis shows broad expression 
of Hirschsprung’s disease-associated genes 
across neural and ICC/SMC cells, implicating 
these cell subsets in pathogenesis.” 
1.16 R2:7) Does Figure 3e show 
expression in the myenteric 
plexus or mesentery? The 
explanation “outside the 
myenteric plexus” (in figure 
legend) is a bit unclear. 
Figure 3e imaging shows DHH+ cells in the 
mesentery. We have clarified this in the figure 
legend. Thank you. 
1.17 R2:8) Please correct the citing of 
Figure 3 in the results section, 
most are not updated. 
We corrected it in text, thank you. 
1.18 R2:9) Carefully check the 
nomenclature in Figure 3 and 
make sure the same names are 
used in a-b as f (for example 
ENCC is not used in the a-b, but 
in f). Also recheck the 
supplementary tables for the 
nomenclature used. 
We have now unified the nomenclature in 
Figure 3 and related Supplementary Figures, 
thank you. 
1.19 R2:10) The difference in Ret 
expression between small (SI) 
and large intestine (LI) is with the 
revised clusters less 
pronounced, and it is doubtful 
whether it is worth high-lighting. 
Branch A (IN) appears even to 
have higher expression in SI 
than LI. The most interesting is 
probably your first sentence, that 
Ret remains in Branch A, but is 
downregulated in Branch B, 
progenitors and glia. The 
comparison between SI and LI 
with regards to Zeb2 and Ednrb 
is ok, but rephrase the sentence 
so that it is clear that you 
compare SI and LI (it was not in 
the latest revision). Note 
however that LI is always going 
to lag behind SI in its 
development due to the rostral- 
caudal colonization of the gut, 
and general differentiation of the 
embryo in an rostral to caudal 
fashion, so the changes might be 
related to this phenomena. 
Although then Sox10 would also 
be enriched in LI, which it is not 
so your observed LI-SI 
differences may be unrelated to 
the general differentiation. 
Thank you. 
 
We have changed the main text as follows: 
 
“Interestingly, ZEB2 and EDNRB were more 
highly expressed across colonic glia and 
neuroblast cells compared to equivalent 
small intestinal subsets (Figure 3f). Any 
differences in expression between regions 
may also be due to the developmental lag 
of the large intestines. In addition, key 
ligands implicated in Hirschsprung’s disease, 
including GDNF, NRTN and EDN3 were 
primarily expressed by mesothelium, smooth 
muscle cells (SMC) and interstitial cells of 
Cajal (ICC) (Supplementary Fig. 5j), as 
described previously.” 
1.20 R2:11) Some mistakes in Figure Apologies for the typos, we have now 
 3: corrected this in Figure 3. 
 Please go through the gene  
 names to make sure there are no  
 typos.  
 -Branch B says Dlx1 at pcw12-  
 17 while it Dlx5 at pcw 6-11. Is  
 this  
 
correct or should it be Dlx5 at 
 
 both stages.  
 -Neurog6 in Branch A (IN) –  
 should it be Neurod6?  
2.1 Referee #4 (Remarks to the 
Author): 
 
The investigators have 
performed a basic re-analysis of 
some of the front part of the 
manuscript, added and clarified 
sample numbers and added new 
spatial transcriptomics and 
smFISH data. In general, 
moderate changes to their data 
visualization have simplified 
and/or clarified some of their 
major messages, including 
improved clarity wrt their choices 
for their ligand receptor 
mappings. They have restricted 
their Hirschsprung's associated 
gene list, and re-formulated/re- 
named some of their clusters. I 
agree with the author's statement 
that tracking fetal time-course 
with respect to proximal to distal 
migration likely should be held 
for a more detailed 
Hirschsprung's focused effort, 
given the difficulty of fetal tissue 
capture. The relegation of the 
(often rare subsets) in CD vs. UC 
is appropriate (given the 
substantial overlap between 
many clusters), with a space- 
efficient summarizing heat-map 
We thank the reviewer for their positive 
comments about the revised manuscript. 
 
We appreciate the suggestion to reorganise 
Figure 1 to contain essential information. We 
do think that overview of the dataset and cells 
covered in the manuscript helps to orientate 
the readers less familiar with single-cell 
sequencing analysis, have have now 
compressed this plot and provide the updated 












Figure 1: Intestinal cellular census throughout 
life 
a) Schematic of tissue sampling of healthy 
human gut. Number of individual donors 
sampled for scRNA-seq throughout the paper 
are shown in parentheses. b) UMAP 
visualisation of cellular landscape of the human 
intestinal tract coloured by cellular lineage. c) 
Relative proportions of cell lineage as in (b) per 
developmental stage.  d) Proportions of 
BEST4+ enterocytes among all epithelial cells 
 
 kept in Fig 5. This 
comprehensive and 
comprehensively referenced gut 
atlas will 
represent a "must-review" primer 
for GI, neurologic and 
immunologic development and 
disease for advanced level 
trainees. I have a few remaining 
questions and concerns. 
 
Major: 
1. Figure 1 overview 
1. 1b can likely be compressed 
for space. Much of this real 
estate is not that informative. 
in scRNA-seq data per tissue region and 
developmental stage. e) Expression of BEST4 
(antibody: HPA058564) and CSTE (antibody: 
CAB032687) in gut histological sections from 
Human Protein Atlas (proteinatlas.org). f) 
Dotplot with relative expression of selected 
marker genes within BEST4+ epithelial cells 
from small and large intestines and different 
ages as in (d). Genes highlighted in red are 
discussed in text. The transcripts for f) were 
selected from the Milo analysis. Full list of 
BEST4+ small vs large intestinal transcripts 
are shown in the Supplementary Fig. 3c. 
2.2 2. In reviewing the fascinating 
complexity of the 
enteroendocrine cells, I wonder 
to what extent the very early fetal 
timepoints might reflect 
contamination from the 
pancreatic bud (acknowledged 
for insulin-producing beta, 
endocrine cells in line 148-9) for 
exocrine cell subsets as well. In 
very early development, not sure 
how easy to dissect apart these 
organs. 
Beta cells were observed only in the first 
trimester proximal ileum samples (BRC2258- 
26 cells, BRC2043 - 6 cells and BRC2199- 1 
cell) (Table 2; Supplementary Fig. 4c), while 
differentiated endocrine cells were observed 
across second-trimester and pediatric/adult 
samples. 
 
In the first trimester samples we also observe a 
population of CLDN10+ cells that could be an 
early pancreatic exocrine cell subset as it 
expresses PDX1. The majority of CLDN10+ 
cells were observed in BRC2258 and 
BRC2043 samples, coinciding with a higher 
number of beta cells found in these samples. 
 
We were not able to dissect pancreatic bud in 
the first trimester samples due to the size of 
the bud at that time, low availability of human 
samples and the fragile nature of fetal tissues 
(manipulation of tissues risks damaging the 
proximal ileal region). However, we decided  
not to remove these cells from our analysis and 
the dataset as we believe it opens avenues for 
further integration of this data with other data 
sets (e.g. adult pancreatic datasets for better 
resolution of pancreatic development in 
humans). 
 
Instead, our solution is now in the revised 
  manuscript to clearly outline pancreatic 
populations with a dashed line in the Figure 2 a 
and e and explain it in the figure legend: 
 
“Cells in grey outlined with a black dashed line 




Figure 2: FCGR2A signalling in tuft cells; 
a-b) UMAP visualisation of a) fetal and b) 
postnatal (pediatric and adult) epithelial lineage 
from scRNA-seq data coloured by cell type. 
Key cell types discussed in text are circled with 
a dashed line and arrows depict scVelo paths 
of differentiation towards secretory and 
absorptive enterocytes. c) Relative proportions 
of cell subtypes within total epithelial lineage as 
in (a-b) separated by donor age (row). Units of 
age is years unless specified as weeks (Wk). 
d) Dot plot of TMPRSS2 and ACE2 expression 
by epithelial cell types in the fetal intestine as 
in (a-b). Here and in later figures, color 
represents maximum-normalized mean 
expression of marker genes in each cell group, 
and size indicates the proportion of cells 
expressing marker genes. e) UMAP 
visualisation of enteroendocrine cells (EECs) 
from fetal, pediatric and adult scRNA-seq 
datasets, where arrows depict differentiation 
paths inferred from scVelo analysis. Cells in 
grey outlined with a black dashed line are 
likely developing pancreatic bud 
contamination. f) UMAP visualisation as in (e) 
  showing key genes of NPW+ enterochromaffin 
(EC) cells. g) Heatmap of genes that change 
along the differentiation trajectory from 
NEUROG3+ progenitors to EC cells as 
highlighted by red arrow in (e). Arrows indicate 
known gene associations with EC 
differentiation in mice and organoids. hi) 
Dotplot of expression of key molecules 
upstream and downstream of PLCG2 
activation in tuft cells and pooled absorptive 
(TA and enterocytes) and secretory (paneth, 
goblet and enteroendocrine (EECs)) epithelial 
cells as in (a-b). h) Percent expression of FCү 
receptor by SiglecF+EpCAM+ and SiglecF- 
EpCAM+ cells in wild type mice determined by 
flow cytometry (biological replicates are 
presented by individual points; n=4). i) 
Summary schematic of proposed signaling 
pathways in tuft cells. P values were calculated 
using 2-way ANOVA with Sidak multiple 
comparisons. ****<0.0001. 
2.3 3. 1d. It seems rather unlikely 
that in the adult samples the 
fractions of epithelial cells range 
from < 2% (duodenum, cecum, 
rectum) to well over 15% 
(Sigmoid). I think the general 
concept that transmural vs. 
biopsy samples results in lower 
fractions of epithelial cells seems 
right, however, as presented, I 
feel that this bar-graph is 
misleading especially for the 
within adult comparisons. Is it 
possible that differences in 
sampling capture efficiencies 
account for this? The doublet 
removals (especially problematic 
for epithelial cells and given the 
high fraction of cell removal 
generally)? 
Figure 1d shows the fraction of BEST4+ cells 
amongst all epithelial cells between the 
anatomical regions. Sample capture may 
contribute to the difference in the proportion of 
these cells between regions, however we 
believe this would be minimal since all 
epithelial cell types would incur the same bias 
in capture. We also do not observe a large 
technical variability in BEST4+ cells (Figure 
R4). We suggest that this difference is a true 
reflection of the makeup of the epithelial layer 
between tissue regions. 
 
 
Figure R4: Dotplot where the fold change 
represents the enrichment (or depletion, low 
  fold change in blue) of epithelial cell subsets 
compared with baseline. The local true sign 
rate (LTSR) value represents statistical 
significance of the fold change estimate 
ranging from 0 to 1, where 1 represents a 
confident estimate. BEST4+ enterocytes and 
colonocytes are highlighted in red. 
2.4 4. (MInor) 1d. Consider removing 
the color (or restricting to 
epithelial green), so as to not 
confuse with 1b/c 
Thank you, we have changed the color of the 
1d barplot to epithelial green. Please see 
comment 2.1, Figure 1. 
2.5 5. 1f. Legend doesn't specify 
what the red highlights 
designate. Not sure what the 
basis for transcript inclusion is 
for this gene list 
Thank you, we have addressed this in text: 
 
“ f) Dotplot with relative expression of selected 
marker genes within BEST4+ epithelial cells 
from small and large intestines and different 
ages as in (d). Genes highlighted in red are 
discussed in text. The transcripts for f) were 
selected from the Milo analysis. Full list of 
BEST4+ small vs large intestinal transcripts 
are shown in the Supplementary Fig. 3c. “ 
2.6 2. Figure 2. The RNA velocity 
analyses substantially strengthen 
the opening to this Figure. Figure 
2a (fetal) vs. b (ped/adult). I may 
be mis/over-interpreting the 
scVelo analyses, but how do the 
authors interpret the M cell 
differences between pre- vs. 
post-natal cells? While the post- 
natal analyses appear to make 
sense (M cells from stem cells), 
the M cells in fetal appear far 
from the stem cells. This would 
appear to be in conflict with de 
Lau et al's findings (PMID 
22778137). Does this reflect pre- 
vs. post-natal differences? 
scVelo analysis is influenced by the position of 
the cells within the UMAP space and it is 
possible that the differences seen in pre- vs. 
post-natal M cells are due to cell type numbers 
and composition differences at these 
timepoints. Being close in the UMAP space 
also does not necessarily reflect differentiation 
relationships. 
 
To add to the scVelo analysis, we have 
performed analysis to resolve potential M cell 
position along the crypt-villus axis. For this, we 
use curated genes that are differentially 
expressed along the crypt-villus axis defined by 
Moor et al. (2018) and Parikh et al. (2019) 
(SEPP1, CEACAM7, PLAC8, CEACAM1, 
TSPAN1, CEACAM5, CEACAM6, IFI27, 
DHRS9, KRT20, RHOC, CD177, PKIB, HPGD, 
LYPD8, APOBEC1, APOB, APOA4, APOA1, 
NPC1L1, EGFR, KLF4, ENPP3, NT5E, 
SLC28A2, ADA). We restrict this analysis to 
the small intestinal epithelial cells only (Figure 
R5). 



























Figure R5: Violin plots with crypt-villus axis 
score in fetal (top) and adult (bottom) small 
intestinal epithelial subsets. 
 
 
Pre- and post-natal M cells scored similarly for 
the crypt-villus axis score (0.4-0.5), while we 
observed differences in other secretory cells 
(Goblet cells, Enteroendocrine) that scored 
lower in fetal samples, possibly reflecting their 
immaturity. 
 
Based on this analysis, we believe that the 
difference between pre- and post- natal scVelo 
results reflect the differences in composition 
(low number of M cells in the fetus) rather than 
alternative differentiation paths. 
2.7 3. ILC origins. This may be 
beyond the scope of this 
manuscript, given the small 
number of ILC2 cells identified, 
Thank you for this interesting suggestion. 
Unfortunately, this is beyond the scope of the 
current manuscript due to the low number of 
ILC2 cells in our data. 
 
 but does appear generally 
relevant given the tie-in to IBD in 
Fig 5. Bielecki et al., (PMID 
33536623) show in skin that 
tissue resident innate lymphoid 
cells are sufficient to drive 
inflammation/pathogenicity, 
implying conversion from ILC2 to 
ILC3. Do any of the present data 
support this model (small 
numbers of ILC2 due to 
transition toward ILC3), or do the 
authors think this merely reflects 
organ differences between skin 
and gut? 
 
2.8 4. Data Sharing and 
Supplementary Materials. The 
authors have provided 
exhaustive figures and tables for 
the community, which will be 
incredibly valuable for the 
community at large. 
Thank you. 
2.9 Minor 
1. Consistency wrt number of 
different anatomic sites sampled: 
10 (line 51) vs. 11 (line 84). 
Figure 1a designates even more 
locations. Should be consistent 
or qualify in place the number of 
sites. 
Thank you. 
We have now clarified that in the adult donors 
we have sampled 11 distinct locations, which 
are duodenum (two locations DUO1 and DUO2 
that were pooled in the analysis), jejunum 
(JEJ), ileum (two locations ILE1 and ILE2 that 
were pooled in the analysis), appendix (APD), 
caecum (CAE), ascending colon (ACL), 
transverse colon (TCL), descending colon 
(DCL), sigmoid colon (SCL), rectum (REC), 
and mesenteric lymph nodes (MLN). 
 
We clarify this in methods and main text as 
follows: 
 
“To comprehensively map cell lineages we used 
single-cell RNA sequencing (scRNA-seq) and 
V(D)J analysis of almost half a million cells from 
up to 5 anatomical regions in the developing and 
up to eleven distinct anatomical regions in 
healthy pediatric and adult human gut. “ 
 
“Here, we create a single-cell census of the 
healthy human gut, encompassing around 
428,000 cells from small and large intestines as 
  well as associated lymph nodes during in utero 
development, childhood and adulthood.” 
 
Methods: 
“Samples were collected from 11 distinct 
locations, including duodenum (two locations 
DUO1 and DUO2 that were pooled in the 
analysis), jejunum (JEJ), ileum (two locations 
ILE1, ILE2 that were pooled in the analysis), 
appendix (APD), caecum (CAE), ascending 
colon (ACL), transverse colon (TCL), 
descending colon (DCL), sigmoid colon (SCL), 
rectum (REC), and mesenteric lymph nodes 
(mLN). “ 
2.10 2. Line 457: change Nerog3+ to 
Neurog3+ 
Changed, thank you. 
2.11 3. Line 260: Change 
parentheses to (beta chain of 
gut-specific a4b7 integrins) 
Changed, thank you. 
 
 
Reviewer Reports on the Second Revision: 
 
Referee #3 (Remarks to the Author): 
 
All concerns have been dealt with satisfactory and I just found a few remaining typos and small 
errors that needs attention. 
Figure 1B. Please change “Neuronal” to “Neural” as you show developing glia and neurons. 
Figure S2d. Please change “Neuronal” to “Neural” as you show developing glia and neurons. 
Figure 3a. Both Onecut2 and 3 appear rather specific to Branch A3, You could mention both 
(Onecut2/3) 
Table 1 Morarach et al corrections: 
i) Developing (E15.5 and E18.5) and <b>juvenile (P21)</b> ENS from mouse small intestine. 
ii) For E15.5 and E18.5, Wnt1-Cre x R26Tom mice were used (to capture whole ENS including all 
stages of differentiation), while juvenile datasets were produced from Baf53b-Cre to enrich for 
neurons only. 
iii) Clarify the new model: “Define a molecular taxonomy of 12 enteric neuron classes within the 
myenteric plexus of the adult mouse small intestine. Embryonic ENS uncovers a novel principle of 
neuronal diversification, where two neuron classes arise through a binary neurogenic branching 
(Branch A and B) <b>and all other classes via postmitotic differentiation.”</b> 
Table 1 Current study corrections: 
i) Neuronal – Change to “Neural” 
ii) Comparable clusters observed in Fawkner-Corbett et al., Cell, 2021. However, the annotations 
are based on the mouse data focusing on <b>gliogenesis</b> and neurogenesis branching 










Author Rebuttals to Second Revision: 
 
Referee #3: 
Remarks to the Author: 
All concerns have been dealt with satisfactory and I just found a few remaining typos 
and small errors that needs attention. 
 
1. Figure 1B. Please change “Neuronal” to “Neural” as 
you show developing glia and neurons. 
Thank you, changed. 
2. Figure S2d. Please change “Neuronal” to “Neural” 
as you show developing glia and neurons. 
Thank you, changed. 
3. Figure 3a. Both Onecut2 and 3 appear rather 
specific to Branch A3, You could mention both 
(Onecut2/3) 
Thank you, updated with both 
genes. 
4. Table 1 Morarach et al corrections: 
i) Developing (E15.5 and E18.5) and juvenile (P21) 
ENS from mouse small intestine. 
Thank you, the table is now 
updated. 
5. ii) For E15.5 and E18.5, Wnt1-Cre x R26Tom mice 
were used (to capture whole ENS including all 
stages of differentiation), while juvenile datasets 
were produced from Baf53b-Cre to enrich for 
neurons only. 
Thank you the table is now 
updated. 
6. iii) Clarify the new model: “Define a molecular 
taxonomy of 12 enteric neuron classes within the 
myenteric plexus of the adult mouse small intestine. 
Embryonic ENS uncovers a novel principle of 
neuronal diversification, where two neuron classes 
arise through a binary neurogenic branching 
(Branch A and B) and all other classes via 
postmitotic differentiation.” 
Thank you, it has been 
updated according to 
reviewer’s suggestion. 
7. Table 1 Current study corrections: 
i) Neuronal – Change to “Neural” 
Thank you, changed. 
8. ii) Comparable clusters observed in Fawkner- 
Corbett et al., Cell, 2021. However, the annotations 
are based on the mouse data focusing on 
gliogenesis and neurogenesis branching 
(Morarach et al., NatureNeuroscience , 2021). 
This has been updated, thank 
you. 
 
 
 
